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Alzheimer’s disease (AD) is a neuro-
degenerative disease with a complex 
genetic background. Several risk 
genes have been identified in AD, 
but for the most part, their biological 
function in the disease pathogenesis 
is still elusive. This thesis focuses on 
elucidating the genetic and biologi-
cal mechanisms of known as well as 
novel risk genes in the molecular 
pathogenesis of AD. The primary 
focus is set to NR1H3, GGA3 and 
UBQLN-1 genes. These studies ad-
vance our knowledge related to mo-
lecular mechanisms of AD and may 
provide new potential targets for the 
development of novel biomarkers and 
therapeutic interventions in AD.
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ABSTRACT
Alzheimer’s disease (AD), the most common cause of dementia, is believed to be initiated
by the accumulation of amyloid- (A) peptide in the brain parenchyma. In the rare,
familial form of AD (FAD), autosomal dominant mutations in three genes; APP encoding
amyloid precursor protein, PSEN1 and PSEN2 encoding presenilin 1 and 2, lead to
increased production of A. The common, so called sporadic form of AD, in turn, has been
hypothesized to be caused by deficits in A degradation and clearance; this form of the
disease is clearly influenced by a combination of genetic and environmental risk factors.
The 4 allele in the APOE gene encoding apolipoprotein E is the major risk factor for AD,
but there are also several other genetic risk factors which make minor contributions. In
recent years, genome-wide association studies (GWAS) implemented with large sample
cohorts have revealed new AD risk genes. However, in many cases the underlying
molecular mechanisms of these genes have remained elusive. This thesis aimed at assessing
the role of known and novel risk genes involved in AD pathogenesis using in vitro cell
culture models, an in vivo AD mouse model, as well as clinical and neuropathological
sample cohorts. More specifically, the focus was on factors affecting the production or the
degradation and clearance of A.
Study I examined 12 genes (MMEL1, ECE1, ECE2, AGER, PLG, PLAT, NR1H3, MMP3,
LRP1, TTR, NR1H2, and MMP9) known to be involved in A degradation and clearance on
the basis of the literature and investigated their role in AD among a Finnish case-control
cohort consisting of altogether ~1300 subjects. The genetic variations in LRP1, TTR and
NR1H3 genes were found to nominally affect the risk of AD, age of onset, or the
cerebrospinal fluid (CSF) biomarker levels. However, after adjusting the p-values for
multiple comparisons, none of the results remained statistically significant.
The effects of the variation in NR1H3 gene encoding liver X receptor  (LXR) were
studied  in  more  detail  in  study  II  using  a  human  brain  sample  set  from  87  subjects  with
neuropathologically well-characterized AD-related neurofibrillary changes. Transcriptional
activation of LXR induces the expression of APOE, ABCA1 and ABCG1, which have been
shown to lead to an increase in APOE-dependent clearance of A, making LXR a potential
therapeutic target. The genetic variation in NR1H3 was found to affect the mRNA levels of
NR1H3 and the soluble A42 levels. These results were in agreement with the findings of
study I  and indicate that a variation in NR1H3 may modulate the progression of AD.
Study III investigated the role of two factors regulating the levels of -site APP cleaving
enzyme 1 (BACE1), an initial and rate-limiting enzyme in A production, using
independent case-control, family-based, and neuropathological sample cohorts. GGA3
(Golgi-localized, -ear containing ADP ribosylation-binding factor 3) is an adaptor protein
involved in the lysosomal degradation of BACE1, whereas phosphorylation of eIF2
(eukaryotic translation initiation factor 2) regulates BACE1 at the translational level. The
results from the analysis of two human post-mortem brain sample sets emphasized the
central role of GGA3 and eIF2 in the cellular processes relevant to AD pathogenesis.
Despite the significant genetic findings from two independent sample cohorts, the results
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from meta-analysis of all five cohorts available for this study did not provide support for
the concept that common GGA3 polymorphisms would contribute to the risk of AD.
Ubiquitin-like protein ubiquilin-1 is another protein which has been shown to associate
with AD at both the genetic and functional levels. In study IV, it was decided to investigate
the expression of ubiquilin-1 in human AD brain and the effects of ubiquilin-1 on BACE1.
Ubiquilin-1 expression was found to be reduced in human brain according to the severity
of AD. Results from in vitro cell culture experiments indicated that overexpression of
ubiquilin-1 could increase the levels of BACE1 protein, which was supported by the
findings from in vivo AD mouse model using lentivirus-mediated ubiquilin-1
overexpression. The mechanistic in vitro assessments imply that overexpression of
ubiquilin-1 stabilizes BACE1 due to decreased degradation of this protein in the lysosomal
compartment. These findings suggest that the altered levels of ubiquilin-1 and its
relationship with BACE1 may play a role in AD pathogenesis.
In summary, this thesis provides novel information on the genetic and the functional role
of specific factors associated with AD pathogenesis. These findings may point the way to
new potential targets for biomarker and drug research as well as knowledge for
personalized medicine in the future.
National Library of Medicine Classification:  QU 475, QU 500, QZ 50, WT 155
Medical Subject Headings: Alzheimer Disease/pathology; Genetics; Genes; Gene Expression; Genetic
Variation; Amyloid beta-Peptides;  Orphan Nuclear Receptors;  Brain; Neurofibrils; Amyloid Precursor
Protein Secretases; Adaptor Proteins, Vesicular Transport; Transcription Factors; Ubiquitins; Cells, Cultured;
Disease Models, Animal
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TIIVISTELMÄ
Alzheimerin tauti (AT) on yleisin dementian aiheuttaja, jonka keskeinen tekijä on amyloidi-
 (A) –peptidin kertyminen aivoihin. Pieni osa AT-tapauksista selittyy mutaatioilla
kolmessa geenissä (APP, PSEN1 ja PSEN2), jotka koodaavat amyloidiprekursori-, sekä
preseniliini 1 ja 2 –proteiineja. Mutaatiot näissä geeneissä aiheuttavat muutoksia A:n
tuotannossa ja johtavat sairastumiseen AT:iin yleensä ennen 65. ikävuotta. Yleisimmin tauti
ilmenee myöhemmällä iällä ja näiden tapausten arvellaan johtuvan A:n hajotukseen
liittyvistä ongelmista. Tässä myöhäisiän tautimuodossa useat geneettiset riskitekijät
yhdessä ympäristötekijöiden kanssa vaikuttavat sairauden syntyyn. Merkittävin
geneettinen riskitekijä AT:ssa on apolipoproteiini E:tä koodaavan APOE-geenin epsilon-4
4) -alleeli.  Sen lisäksi AT:iin liittyviä geenimuotoja, joilla on pieni riskivaikutus, on
raportoitu satoja. Tästä huolimatta taudin perimmäinen syy, samoin kuin suurin osa
riskigeenien biologisista vaikutusmekanismeista, on edelleen selvittämättä. Tässä
väitöskirjatyössä pyrittiin kartoittamaan uusia AT:n riskigeenejä sekä selvittämään niiden
ja jo aiemmin tunnettujen riskigeenien molekyylitason vaikutuksia. Erityisesti pääpaino oli
tekijöissä, jotka vaikuttavat A:n tuotantoon tai hajotukseen.
Ensimmäisessä osatyössä valittiin 12 geeniä (MMEL1, ECE1, ECE2, AGER, PLG, PLAT,
NR1H3, MMP3, LRP1, TTR, NR1H2 ja MMP9), joiden tiedetään aiemman kirjallisuuden
perusteella osallistuvan A:n hajotukseen ja poistamiseen aivoista. Näiden geenien roolia
AT:ssa tutkittiin käyttämällä noin 1300 henkilöstä koostuvaa, itäsuomalaista tapaus-
verrokkiaineistoa. SNP-pohjaisella menetelmällä havaittiin, että muutokset LRP1-, TTR- ja
NR1H3-geeneissä vaikuttivat AT:n sairastumisriskiin, alkamisikään tai selkäydinnesteen
merkkiaineproteiinien tasoihin. Nämä tulokset eivät kuitenkaan olleet tilastollisesti
merkittäviä tilastollisten korjausten jälkeen.
LXR-proteiinia (Liver X reseptori ) koodittavan NR1H3-geenimuutosten vaikutuksia
tutkittiin tarkemmin toisessa osatyössä käyttäen 87 AT-potilaan neuropatologista
aivonäytesarjaa. LXR:n aktivaatio lisää APOE-, ABCA1- ja ABCG1-geenien ilmentymistä,
minkä on näytetty johtavan APOE-välitteisen A:n hajotuksen lisääntymiseen. Muutokset
NR1H3-geenissä vaikuttivat NR1H3:n lähetti-RNA-tasoihin sekä liukoisen A42-peptidin
tasoihin AT-potilaiden aivoissa. Saadut tulokset olivat samansuuntaisia ensimmäisessä
osatyössä tehtyjen havaintojen kanssa, ja ne yhdessä viittavat siihen, että muutokset
NR1H3-geenissä voivat vaikuttaa AT:n etenemiseen.
Kolmannessa osatyössä tutkittiin kahta, A:n tuotannossa keskeisen -
sekretaasiproteaasin (BACE1) tasoihin vaikuttavaa tekijää. GGA3 (Golgi-localized, -ear
containing ADP ribosylation-binding factor 3) on proteiini, joka osallistuu BACE1:n
kuljettamiseen endosomeista hajotettavaksi lysosomeihin. eIF2 (eukaryotic translation
initiation factor 2) on puolestaan translaatiotekijä, jonka seriini-51-aminohapon
fosforylaatio johtaa BACE1:n proteiinitasojen nousuun. Tässä tutkimuksessa useat tulokset
kahdesta eri humaaniaivonäytesarjasta tukevat sekä GGA3:n että eIF2:n keskeistä roolia
AT:n patogeneesissä. Huolimatta siitä että kahdessa itsenäisessä potilasaineistossa
havaittiin tilastollisesti merkittävä geneettinen tulos, kaikkiaan viidestä erillisestä
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aineistosta tehty meta-analyysi ei tue käsitystä siitä, että GGA3-muutokset vaikuttaisivat
AT:n riskiin.
Ubikiliini-1 on ubikitiinin kaltainen proteiini, jonka yhteys AT:n patogeneesiin on
osoitettu niin geneettisellä kuin toiminnallisellakin tasolla. Neljännessä osatyössä havaittiin
ubikiliini-1-tasojen alenevan AT-potilaiden aivoissa sairauden edetessä. Samalla havaittiin
yhteys ubikiliini-1- ja BACE1-tasojen välillä. Solumalleista saadut tulokset osoittivat että
ubikiliini-1:n yli-ilmentäminen lisää BACE1-tasoja. Lisäksi havainnot lentivirusvälitteisestä
ubikiliini-1:n yli-ilmentämisestä AT-hiirimallin aivoissa tukivat tätä tulosta. Solumalleilla
tehdyt tutkimukset ilmiön toiminnallisesta mekanismista viittaavat siihen, että ubikiliini-
1:n yli-ilmentäminen stabiloi BACE1-proteiinia ohjaamalla sitä pois lysosomaaliselta
hajotusreitiltä. Yhdessä nämä tulokset viittaavat siihen, että ubikiliini-1- ja BACE1-tasoilla
on yhteys ja että muutokset niiden tasoissa voivat vaikuttaa AT:n patogeneesiin.
Tämän väitöskirjatyön tulokset tarjoavat uutta tietoa tutkittujen geenien ja proteiinien
vaikutuksista AT:n patogeneesiin. Tätä tietoa voidaan tulevaisuudessa hyödyntää
mahdollisten uusien terapiakohteiden sekä diagnostisten merkkiaineproteiinien
kartoittamisessa ja kehittämisessä.
Luokitus: QU 475, QU 500, QZ 50, WT 155
Yleinen suomalainen asiasanasto: Alzheimerin tauti; patogeneesi; geenit; geenitutkimus; geeniekspressio;
peptidit; proteiinit; soluviljely; koe-eläimet
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1 Introduction
Alzheimer’s disease (AD), the most common cause of dementia, is a progressive
neurodegenerative disease, causing severe memory and cognitive impairments, inabilities
to perform basic functions of daily life and ultimately to death. The prevalence of AD
before age of 65 is very low, but displays an almost exponential increase with aging. While
less than 1% of individuals aged 60–64 years are affected by AD, almost every third
individual aged 85 years or older is demented, mostly caused by AD (Ferri et al., 2005).
Since populations are aging rapidly, it has been estimated that the worldwide prevalence of
AD will double every 20 years until 2040 when the number of AD patients will have
reached 80 million (Ferri et al., 2005). This will cause huge individual suffering and
represent an unbearable economic burden for societies.
Amyloid plaques, composed of extracellular aggregates of -amyloid (A) –peptide,
together with intracellular neurofibrillary tangles (NFTs) are the central neuropathological
hallmarks of AD (Hardy and Selkoe, 2002). Brain imaging and cerebrospinal fluid (CSF)
biomarker studies have shown that the accumulation of A begins years before the clinical
symptoms  such  that  the  A pathology  is  already  full-blown  and  the  loss  of  neurons  has
progressed at the time when clincal symptoms appear (Jack et al., 2010). A has been
postulated to trigger downstream effects like synaptic dysfunction, microglial and
astrocytic activation, oxidative stress and formation of intracellular neurofibrillary tangles
consisting of hyperphosphorylated tau protein (Hardy and Selkoe, 2002). These events lead
to synaptic dysfunction, neurotransmitter deficits, loss of neurons and development of
dementia. The NFTs, another neuropathological hallmark of AD, are intracellular
aggregates of hyperphosphorylated tau protein. These aggregates are observed first in the
entorhinal cortex and they spread further to the hippocampus and finally throughout the
neocortex as the disease progresses (Braak et al., 2006a).
–peptide is produced from amyloid precursor protein (APP) after sequential cleavage by
-secretase known as -site-APP-cleaving-enzyme 1 (BACE1) and -secretase complex
(Selkoe, 2001). APP is a type-1 transmembrane protein, which has a large amino-terminal
extracellular domain and a short cytoplasmic tail. APP processing can be initiated by
BACE1, leading to the amyloidogenic pathway and the generation of APP C-terminal
fragment (CTF) called C99. Alternatively, -secretase initiates the enzymatic processing by
cleaving APP within the A domain leading to the non-amyloidogenic pathway and the
formation of CTF known as C83. These CTFs are subsequently cleaved by -secretase,
leading to the formation of A (from C99) or p3 (from C83) peptides (Selkoe, 2001).
Depending on the specific site of -secretase cleavage, different lengths of A species are
formed. A40 is the most common form while A42 is fibrillogenic and more prone to
aggregate and thus can be considered as a more toxic form.
There are rare familial forms of AD (FAD) caused by autosomal dominant inheritance of
mutations in the APP, PSEN1 and PSEN2 genes (Tanzi, 2012). Individuals carrying at least
one of these mutations inevitably develop AD, often before 65 years of age. At the
biochemical level, these mutations affect the processing of APP, leading to an increase in
the total levels of the A–peptide or to an increase in the ratio of A42:A40 (Tanzi, 2012).
Excluding the cases with rare autosomal dominant mutations, AD is a genetically complex
and heterogeneous disorder. Variation in apolipoprotein E gene (APOE) has been shown to
account for a significant portion of the genetic risk in several independent studies. One
copy of the APOE
4 allele increases the risk of AD by ~3.2 –fold whereas two copies of 4
2increase the risk by almost 15-fold higher as compared to individuals with two copies of the
most common 3 allele (Bettens et al., 2013). In addition to APOE, hundreds of risk genes
have been identified in candidate-gene based association studies, mostly conducted with
relatively small sample sizes. However, these genes have been shown to exert only modest
risk effects and after systematic meta-analysis only a small proportion of the results have
remained statistically significant (Tanzi and Bertram, 2005). The first genome-wide
association study (GWAS) in AD genetics was published in 2007 (Grupe et al., 2007).
Subsequently, several novel risk genes have been discovered as a result of international
GWAS collaboration; CLU, CR1, PICALM (Harold et al., 2009; Lambert et al., 2009), BIN1
(Lambert et al., 2011), EPHA1, ABCA7, MS4A4A/MS4A6E, CD33 and CD2AP (Hollingworth
et al., 2011; Naj et al., 2011). The risk effects of these genes are ~10 – 20% either increasing
the risk or conferring a protective effect (Bettens et al., 2013). Despite the modest effects of
individual genes, it is apparent that several susceptibility genes may act together in a
complex interaction with environmental factors to affect the risk of AD (Tanzi and Bertram,
2005).
APOE or  the  other  risk  genes  have  not  been  shown to  directly  affect  A production.  The
underlying functional mechanisms of these genes are associated with lipid metabolism, A
aggregation and clearance, synaptic functions, immune system and inflammation (Bettens
et al., 2013). Indeed, the accumulation of A can be affected not only by changes in its
production but also by changes in its degradation and clearance. Thus, enzymes involved
in  A degradation such as insulin-degrading enzyme (IDE), neprilysin (NEP) among
others, are important in the regulation of brain A levels and in primary focus in AD
research (Vepsalainen et al., 2007; Miners et al., 2008).
At the moment, three acetylcholinesterase inhibitors (AChE-Is) donepezil, rivastigmine and
galantamine and one NMDA receptor antagonist, memantine, are drugs approved for the
treatment of AD. However, these neurotransmitter-based therapies provide only mild
symptomatic relief. Unfortunately, at present, no medication exists to cure or even slow
down the progression of the disease.
This study aimed to identify novel risk genes using the Finnish AD case – control –cohort,
especially to undertake an assessment of the underlying molecular mechanisms connected
to A homeostasis. Revealing the risk genes and their functional mechanisms in the disease
pathogenesis is a huge challenge for AD research. However, this is essential groundwork
on the route to identifying novel disease biomarkers and finding new drug targets for
facilitating earlier diagnosis and efficient treatment of AD patients in the future.
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2.1 CLINICAL ASPECTS AND NEUROPATHOLOGY OF ALZHEIMER'S
DISEASE (AD)
2.1.1 Clinical features
AD is the most common form of dementia. It is characterized by a progressive cognitive
decline, usually starting with impairment of short-term memory, gradually disturbing all
cognitive functions and leading to a loss independence and inability to take care of basic
functions of daily life (Galasko et al., 1997). AD is divided into two subgroups, based on the
age when the clinical symptoms occur. An onset age of 65 years is used as the cut-off value
to discriminate between early-onset AD (EOAD) and the most common form, late-onset AD
(LOAD) (Rademakers et al., 2003). These two forms are clinically and pathologically
identical, although the progression of disease is more rapid in EOAD. Only a small
proportion (~10%) of EOAD cases are FAD cases caused by autosomal dominant mutations
in APP, PSEN1 or PSEN2 genes.
A mild decline of cognitive functions and a reduced speed of mental processing are features
of healthy, nondemented aging (Birren and Fisher, 1995), whereas cognitive impairment
and memory decline in AD are progressive changes the from patient’s prior abilities
affecting daily functions (Morris, 1993). In the early phase of AD, the working memory,
long-term declarative memory, and implicit memory are influenced to a lesser extent than
short-term declarative memory (Tarawneh and Holtzman, 2012). As the disease progresses,
the variety of symptoms can consist of defects in problem solving, decision making,
language skills, visuospatial perception and changes in personality. Eventually, in the later
phases, the speechlessness, incontinence, and general unresponsiveness occur (McKhann et
al., 1984). Rates of disease progression and survival vary significantly among different
patients. There is also variability among individuals in the age of onset, family history, and
the appearance of possible behavioral or motor abnormalities (Tarawneh and Holtzman,
2012). Furthermore, in many cases, in parallel with AD there are mixed pathologies such as
Lewy body dementia and vascular dementia, which complicates the accurate clinical
diagnosis.
The clinical diagnosis of dementia is implemented using commonly accepted sets of criteria
such as The National Institute on Neurological and Communicative Disorders and Stroke
and the Alzheimer Disease and Related Disorders Association (NINCDS/ADRDA) criteria
(McKhann et al., 1984) or The Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) criteria. These two criteria are comparable and are the most
commonly used. The NINCDS/ADRDA criteria categorize AD into “probable,” “possible,”
or “definite” and it has a good sensitivity (81%) and specificity (70%) for “probable” AD
(Knopman et al., 2001). However, the ability to discriminate between AD and other
dementias is less accurate (23–88%) (Ballard et al., 2011). For the diagnosis of “definite” AD
histopathological evidence from autopsy is required and this can only be obtained post
mortem.
Several biomarker and brain imaging studies have shown that neuropathological events,
particularly the accumulation of A peptide, precede the clinical symptoms by several
years (Serrano-Pozo et al., 2011). This raises the need for recognition of the pre-dementia
4phase of AD, in other words identification of the earliest clinical features of disease before
any functional impairment is evident. The term mild cognitive impairment (MCI) has been
proposed to be a condition of the type of impairment which is intermediate between
normal aging and the diagnosis of dementia or AD (Petersen, 2004). In this early, but
abnormal state, the patient displays a mild memory decline, but exhibits no functional
decline. The subjects with MCI are at high risk for further cognitive decline and progression
to AD, as their annual rate of AD diagnosis is 10-15% as compared to the annual rate of 1-
2% in non-MCI subjects (Petersen et al., 2009). However, not all MCI subjects progress to
AD. Some of them remain stable, some might develop non-AD dementias.
2.1.2 Neuropathology
The histopathological hallmarks of AD include lesions consisting of -amyloid plaques and
NFTs (Trojanowski and Lee, 2000; Crews and Masliah, 2010), which are accompanied by
inflammatory events such as astrogliosis and activated microglia (Itagaki et al., 1989). In
addition, other typical features of AD brain are loss of neurons and synaptic elements
(Scheff et al., 2006; Gomez-Isla et al., 1996; Knowles et al., 1999). Furthermore, cerebral
amyloid angiopathy (CAA), i.e. the accumulation of A in the walls of small vessels, is a
common finding in the brains of AD patients (Querfurth and LaFerla, 2010). At the
macroscopic level a symmetric cortical atrophy affecting the medial temporal cortex and
expansion of the lateral ventricles can be detected in the early phase of clinical AD by
magnetic resonance imaging (MRI) (Dickerson et al., 2009; Dickerson et al., 2011). The -
amyloid plaques result from the abnormal extracellular accumulation and deposition of the
 peptides with 40 or 42 amino acids (A40 and A42), which are produced in the normal
metabolism of APP. Since it is more prone to aggregate, A42 is more abundant than A40
within the plaques (Serrano-Pozo et al., 2011). The widely used morphological classification
of -amyloid plaques is based on their staining with dyes specific for the -sheet
conformation such as Thioflavin-S or Congo red. Thioflavin-S positive dense-core, also
referred to as a neuritic plaque typically occurs along with dystrophic neurites, reactive
astrocytes and microglial cell activation, and are associated with synaptic loss (Itagaki et al.,
1989; Knowles et al., 1999; Masliah et al., 1990; Masliah et al., 1994; Vehmas et al., 2003). The
presence of these neuritic plaques is generally associated with the existence of cognitive
impairment, and thus it can be used for the neuropathological diagnosis of AD (Serrano-
Pozo et al., 2011). In contrast, Thioflavin S negative diffuse plaques are amorphous -
amyloid deposits that are commonly present in the brains of cognitively intact elderly
people and usually they are not accompanied with glial responses or synaptic loss (Masliah
et al., 1990). Thus, the neuropathological boundaries between normal aging and AD
dementia are not clear-cut.
As mentioned, the A load has been estimated to reach its plateau already at the onset of
the cognitive symptoms (Ingelsson et al., 2004) and there is not even a significant growth in
the size of the A plaques as the disease progresses (Hyman et al., 1993). Thus, the total or
neuritic A load does not correlate with the progression of clinical symptoms of dementia
(Ingelsson et al., 2004; Hyman et al., 1993; Arriagada et al., 1992; Bierer et al., 1995; Gomez-
Isla et al., 1997; Giannakopoulos et al., 2003). In addition, the spatiotemporal development
of A pathology is less predictable than the progression of NFTs. However, in general, A
plaques accumulate mainly in the isocortex, whereas the entorhinal cortex, hippocampus,
the basal ganglia, and the cerebellum, are less and only later affected. Furthermore, even in
the isocortical areas, primary sensory, motor, and visual areas are involved to a lesser
extent than the associative areas in isocortex (Arnold et al., 1991; Braak and Braak, 1991).
NFTs consist of aberrantly folded and abnormally hyperphosphorylated microtubule-
associated protein tau (Iqbal et al., 2005). Tau is a normally abundant axonal protein,
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hyperphosphorylated tau is insoluble, lacks affinity for microtubules, and forms paired
helical filament (PHF) structures, which subsequently aggregate into NFTs (Iqbal et al.,
2005). Opposite to the A load, the spatiotemporal pattern of progression of NFTs is
relatively predictable (Braak et al., 2006a; Arnold et al., 1991; Braak and Braak, 1991). The
neurofibrillary degeneration starts from the transentorhinal and entorhinal cortex,
progresses to hippocampus and associative isocortex, while the primary sensory, motor,
and visual areas of isocortex are the last to be affected. The neurofibrillary degeneration has
been divided into six stages by Braak and Braak (Figure 1). In addition to predictability,
progression of tau pathology has correlated rather well with the progression of clinical
symptoms of AD (Ingelsson et al., 2004; Arriagada et al., 1992; Bierer et al., 1995; Gomez-
Isla et al., 1997; Giannakopoulos et al., 2003). Furthermore, the selective topographical
distribution of NFTs correlates with the neuropsychological profile typical for AD. Despite
the correlation described above, it remains unclear whether NFTs are causative or simply
correlate with neuronal loss (Gomez-Isla et al., 1997; Iqbal and Grundke-Iqbal, 2002;
Kimura et al., 2010).
Figure 1. Progression of neurofibrillary pathology at different Braak stages represented in coronal
hemisphere sections immunostained for hyperphosphorylated tau. NFT pathology initiates from entorhinal
and transentorhinal cortex and progresses to hippocampus before the clinical symptoms occur
(Transentorhinal stages; I-II). Next, NFT pathology worsens in hippocampus and reaches the medial
temporal lobe and at this point, mild cognitive impairment or early AD usually appears (Limbic stages; III-
IV). NFT pathology progresses further in medial temporal lobe and finally to the cortical association areas
(Neocortical stages; V-VI) when fully developed AD occurs. (Adapted from Braak et al., 2006, Acta
Neuropathol 112:389–404, with kind permission of Springer Science and Business Media)
62.1.3 CSF biomarkers and brain imaging
The  intrinsic  uncertainty  in  clinical  diagnosis  of  AD has  led  to  the  search  for  informative
diagnostic markers. At the moment, cerebrospinal fluid (CSF) biomarkers and
neuroimaging provide valuable tools to confirm the clinical diagnosis. Since
neuropathological changes, including the accumulation of A, synaptic dysfunction, tangle
formation and brain atrophy, take place many years prior to the clinical symptoms (Figure
2), there is a clear need to be able to make an earlier diagnosis. In particular, should
possible disease modifying drugs become available, then the treatment must be initiated
already in predementia stage in order to stop the neurodegeneration as early as possible
(Blennow et al., 2010). There is a clear need for tools that would reflect key factors in the
disease pathogenesis, achieve an earlier diagnosis and help to identify and monitor the
biochemical responses to the drugs in clinical trials. Thus, investigators are seeking new
biomarkers and neuroimaging techniques.
The CSF is an optimal source for seeking AD biomarkers since it is in direct connection
with extracellular space of the brain and consequently reflects biochemical alterations in the
brain (Blennow et al., 2010). Since they represent primary components of neuropathological
lesions in AD, A42 and tau protein levels in CSF have been assessed as potential
biomarkers. The A42 levels have been shown to be approximately 50% lower in the CSF of
AD patients as compared to controls (Sunderland et al., 2003; Blennow, 2004). Tau protein
exists in six isoforms and the longest isoform has a total of 80 potential serine and threonine
phosphorylation sites, of which 39 sites have been verified (Portelius et al., 2008). Total-tau
levels regardless of isoform and phosphorylation status have been shown to increase by
approximately 300% in the CSF of AD patients as compared to controls (Sunderland et al.,
2003; Blennow, 2004). The most commonly used phosphorylated tau (p-tau) assays which
are specific for phosphorylation at either threonine 181 or threonine 231 residues have
revealed a significant increase also in p-tau levels in the CSF of AD patients (Blennow,
2004). A combination of these three biomarkers achieves a higher diagnostic accuracy than
can be obtained with any biomarker alone and these measurements discriminate AD
patients from non-demented controls with sensitivity and specificity values both over 80%
(Blennow, 2004). Several candidate CSF biomarkers in addition to A42 and tau have been
studied including BACE1, sAPP, sAPP, A oligomers, and proteins reflecting neuronal
and synaptic degeneration, but the results have not been encouraging (Blennow et al.,
2010). However, some of these might be useful in clinical trials of drugs affecting APP
processing.
Neuroimaging in AD was previously used to exclude the surgically treatable causes of
cognitive decline but it has now moved to central role, since these technologies provide
diagnostic support by visualizing structural and functional chages in the brain. The most
commonly used neuroimaging technologies are MRI, which includes both structural and
functional options, and positron emission tomography (PET) for assessment of both
cerebral metabolism and -amyloid (Johnson et al., 2012). In contrast to CSF biomarkers,
imaging provides topographical information of different measurable characteristics of AD
pathology.
Structural MRI has been used successfully to image the cerebral atrophy typical in
neurodegeneration and the regional MRI volumes have been shown to correlate with
neuronal counts at autopsy (Bobinski et al., 2000). In MRI, the atrophy is usually first
observed in entorhinal cortex, followed by hippocampus, amygdala, and parahippocampus
(Dickerson et al., 2001; Killiany et al., 2002). These losses of volumes are later detected also
in the temporal isocortex and finally in the entire associative isocortex, which agrees with
7the spreading pattern of the NFT pathology through different brain areas during the course
of the disease (Braak and Braak, 1991).
Functional MRI (fMRI), in turn, provides indirect information of neuronal activity by
measuring alterations in the blood oxygen level–dependent (BOLD) MR signal (Ogawa et
al., 1990; Kwong et al., 1992). Several fMRI studies using episodic memory tasks have
revealed decreased neuronal activity in hippocampus and related structures in the medial
temporal lobe of patients with clinically diagnosed AD (Rombouts et al., 2000; Sperling et
al., 2003). Furthermore, increased prefrontal cortical activity in AD patients has been
reported, indicating that compensatory mechanisms take place due to hippocampal failure
(Sperling et al., 2003).
Figure 2. Neuropathological events during the progression of AD. CSF and PET studies have revealed that
 accumulation precedes clinical symptoms by several years and progresses only gradually after the
clinical symptoms have occurred. Synaptic dysfunction detected by FDG-PET/MRI starts to develop after
the A accumulation has been initiated. CSF Tau levels and the volume loss of brains as measured by
volumetric MRI correlate well with cognitive and clinical function. CSF/PET A levels, in turn, do not
correlate well with the decline in cognitive and clinical function. (Adapted from Brinton, R. D., 2013, Nat.
Rev. Endocrinol. 9: 241–250)
While fMRI indirectly reflects synaptic activity of neurons by detecting changes in blood
flow, blood volume, and the blood oxyhemoglobin/ deoxyhemoglobin ratio, fluoro-deoxy-
D-glucose (FDG)-PET is postulated to primarily reflect the synaptic activity (Johnson et al.,
2012). As the brain relies almost completely on glucose as its source of energy, the glucose
analog FDG can be utilized to measure glucose metabolism. FDG PET has shown good
accuracy in distinguishing patients with probable AD from both normal control individuals
and patients with non-AD dementias achieving both sensitivity and specificity of 86% in
the AD diagnosis (Patwardhan et al., 2004). High -amyloid depositions have been shown
to co-localize with FDG hypometabolism, possibly evidence of local toxicity (Engler et al.,
2006).
The development of novel A ligands, such as Pittsburgh Compound B (PiB), has enabled
direct visualization of fibrillar A in the brain of living individuals using PET imaging. All
currently known A ligands are known to bind to fibrillar A in a beta-sheet conformation
(Ikonomovic et al., 2008). Thus, it is unclear whether the soluble, toxic A oligomers are
detected by PiB PET. However, a relationship may exist between the PiB PET signal and
oligomer concentration based on the belief that there is an equilibrium between the
monomers, oligomers, and fibrillar A. From a clinical perspective, PiB PET is a valuable
tool, since it has been shown to correlate well with autopsy-confirmed A deposits
8(Ikonomovic et al., 2008). Furthermore, the most important contribution of PiB PET may
come from detecting cognitively normal elderly subjects who have an underlying cerebral
 accumulation since this could provide insights into the very initial phase of the disease.
2.2 GENETICS OF AD
2.2.1 Causative gene mutations in familial AD
Family history, meaning the inherited genetic component, is the second strongest risk factor
in AD after advanced age. From a genetic point of view, AD is a dichotomous disease. The
causative autosomal dominant mutations are known to exist in three genes APP, PSEN1
and PSEN2. These mutations lead inevitably to familial AD (FAD), usually before the age of
65. This form of disease is rare, representing ~1% of all AD cases (Bekris et al., 2010).
When the A peptide was initially isolated and its amino acid sequence resolved from AD
brain samples in 1984, it was hypothetized that a mutation in the gene encoding this
peptide would be responsible for AD (Glenner and Wong, 1984). Subsequently, the APP
gene was isolated by several groups and shown to be located in chromosome 21 (Goldgaber
et al., 1987; Kang et al., 1987; Tanzi et al., 1987). APP was characterized as containing 240
kilobases and 18 exons and later it was shown that alternative splicing could lead to three
common protein isoforms; APP695, APP751 and APP770 (Selkoe, 2001). In the early 1990’s,
several pathogenic mutations in APP gene were found, and they were named by the region
of origin, such as Swedish, Dutch and Arctic mutations (Figure 3) (Levy et al., 1990; Goate
et al., 1991; Citron et al., 1992). Today, altogether 24 pathogenic mutations are now known
(Table 1) (Tanzi, 2012). In addition, there exist duplications of the APP gene, meaning that
individuals may have three copies of APP instead of the diploid two copies (Rovelet-Lecrux
et al., 2006). Furthermore, individuals with Down syndrome (DS) have three copies of APP
because of trisomy in chromosome 21. As a consequence of an additional copy, 50% more
APP is produced, leading to augmented A production and early onset dementia.
Virtually all pathogenic APP mutations lead to an increase in the ratio of A42:A40. This
relative increase of A42 augments the aggregation of the peptide into oligomers leading to
formation of -amyloid fibrils (Jarrett et al., 1993). Only the Swedish mutation, which is
actually a double mutation with substitution of Lys to Asn at position 670 and Met to Leu at
residue 671 (K670N/M671L), increases all species of A. The Swedish mutation is the only
APP mutation located next to the -secretase cleavage site and these amino acid
substitutions lead to more efficient -site cleavage (Mullan et al., 1992).
9Figure 3. Schematic structure of the longest human APP isoform APP770 and the autosomal dominant
mutations in APP. APP is a type I transmembrane (transmembrane domain: light grey box and dashed
lines) protein having C-terminus in cytosol and N-terminus in extracellular space. A42 (dark grey box) is
generated by sequential cleavage by -secretase (grey triangle) at position 672 and -secretase (grey
triangle) at position 713. Another -secretase cleavage site is located at position 711 leading to formation
of A40. -Secretase (grey triangle) cleaves APP within the A domain preventing the A generation. Black
arrows show the currently known mutations in APP gene identified from familial AD patients. These
mutations lead to substitution of amino acids indicated by uppercase letters under the arrows. (Adapted
from Thinakaran and Koo, 2008, Journal of Biological Chemistry 283:29615-29619)
It was found shortly after isolation of APP that only a portion of EOAD families were
carrying mutations in this gene. Later, EOAD cases without APP mutations were found to
carry mutations in the PSEN1 gene, encoding presenilin-1 protein, a component of -
secretase complex (Sherrington et al., 1995). Subsequently, a causative mutation also in a
homolog of PSEN1, PSEN2 gene was reported (Levy-Lahad et al., 1995; Rogaev et al., 1995).
These mutations in PSEN1 and PSEN2 genes were responsible for the rest of familial AD
cases without APP mutations. To date, 185 mutations in PSEN1 located on chromosome 14
and 14 mutations in PSEN2 located on chromosome 1 have been reported (Tanzi, 2012). As
the majority of APP mutations, also PSEN1 and PSEN2 mutations increase the ratio of
42:A40.
Table 1. Early onset familial Alzheimer disease genes and their pathogenic effects
Gene Protein Chromosome Mutations Molecular phenotype
APP Amyloid 
precursor protein
21q21 24 Increased A42/ A40 ratio
Increased A production
Increased A aggregation
PSEN1 Presenilin 1 14q24 185 Increased A42/ A40 ratio
PSEN2 Presenilin 2 1q31 14 Increased A42/ A40 ratio
(Adapted from Tanzi 2012, Cold Spring Harb Perspect Med 2012;2:a006296)
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2.2.2 Risk genes in AD
While FAD cases are rare, the majority of AD cases are common, late-onset form (LOAD),
without any causative mutations. However, also these “sporadic” cases are strongly
influenced by a combination of genetic factors. Based on twin and family studies, it has
been estimated that 60-80% of AD involves the inheritance of genetic variants (Gatz et al.,
2006). It should be noted that genetic factors in LOAD do not inevitably lead to the disease,
but they do influence the risk either by increasing or by decreasing it. Thus, the complex
pattern of genetic factors work in concert with enviromental and lifestyle factors
determining the overall risk for the disease.
The majority of genetic risk effect in LOAD comes from variation in apolipoprotein E
(APOE) gene. There are three APOE alleles; 2, 3 and 4 and individual with normal
diploid chromosomes inherits one of these alleles from the mother and one from the father.
APOE
4 has been shown to increase the risk of AD and to decrease the age of onset (table
2). The worldwide frequency of 2, 3 and 4 alleles are 8.4%, 77.9% and 13.7%,
respectively. However, the frequency of risk allele 4 has been reported to be as high as
40% among AD patients (Farrer et al., 1997). Individuals carrying one 4 allele have an
approximately three fold higher risk (OR 3.2) of AD, and people with two copies of 4 have
an ~15 fold higher risk (OR 14.9) of AD as compared to those with the most common
genotype APOE
3 (Farrer et al., 1997). In contrast, the 2 allele exerts a protective effect
against AD: the risk of AD in individuals with APOE genotype 2 (OR 0.6) or 3 (OR
0.6) is lower than in those with 3 genotype (Farrer et al., 1997). Functionally, APOE
protein is known to be involved in mediating lipid metabolism and lipid transport between
different tissue and cell types (Mahley and Rall, 2000). However, in AD, APOE has been
postulated to be involved in the clearance of A from brain (Castellano et al., 2011).
Table 2. The effect of APOE4 on AD frequency and age at onset
Characteristic APOE4
noncarrier
APOE4
heterozygous
APOE4
homozygous
AD frequency (%) 20 47 91
Mean age of clinical onset (years) 84 76 68
(Adapted from Corder et al., 1993, Science 261:921-923)
After the finding of APOE, thousands of candidate-gene-based association studies have
been conducted and hundreds of genes have been tested for association of AD. The results
of these studies have been collected to online database called AlzGene, which provides
updated information and meta-analyses of AD candidate genes
(www.alzgene.org)(Bertram et al., 2007). Most of these studies have been case-control
association studies, which compare single nucleotide polymorphism(s) (SNP) between case
and healthy control groups. Usually these studies have examined a single candidate gene
based on findings emerging from functional studies, which link the candidate gene to AD
pathogenesis. Despite the growing number of candidate-gene-based studies, they have not
revealed any major LOAD risk genes. The main reason for this is the lack of power due to
small sample sizes in individual studies, which usually consist of few hundred cases. The
lack of power often leads to either false-positive or false-negative associations (Bettens et
al., 2013).
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The advances in genetic technologies have enabled new strategies for finding novel AD risk
genes. Genome-wide association studies (GWAS) have made it possible to search through
even millions of polymorphisms simultaneously across the genome in a hypothesis-free
manner. Several GWAS with tens of thousands samples have now been undertaken by
international consortia. These studies have revealed new AD candidate genes, and the
results have been incorporated into the Alzgene database (Table 3). Despite the strong
statistical support for these new candidates, the effects of these genes on the risk of AD are
small. The alterations in the risk of AD with these genes are ~10-20%, while with allelic
variation in APOE, it is ~300-1500% (Tanzi, 2012). Furthermore, a recent two stage meta-
analysis of GWAS data sets consisting of altogether 74,046 individuals identified 11 new
susceptibility loci for AD in addition to the already known GWAS-defined genes (Lambert
et al., 2013).
Table 3. Currently known risk genes revealed in GWA studies and their predicted pathogenic
mechanisms
Gene Protein Location Risk
change
Proposed molecular phenotype
APOE Apolipoprotein E 19q13 ~400-
1500%
Clearance of A; lipid metabolism
CD33 CD33 (Siglec 3) 19q13.3 ~10% Innate immunity; degradation of

CLU Clusterin 8p21.1 ~10% Clearance of A; innate immunity
CR1 Complement component
(3b/4b) receptor 1
1q32 ~15% Clearance of A; innate immunity
PICALM Phosphatidylinositol binding
clathrin assembly molecule
11q14 ~15% Production and clearance of A;
cellular signaling
BIN1 Bridging integrator 1 2q14 ~15% Production and clearance of A;
cellular signaling
ABCA7 ATP-binding cassette subfamily
A member 7
19q13.3 ~20% Lipid metabolism; cellular signaling
CD2AP CD2-associated protein 6p12.3 ~10% Cellular signaling
EPHA1 EPH receptor A1 7q34 ~10% Cellular signaling; innate immunity
MS4A6A/
MS4A4E
Membrane-spanning 4-
domains, subfamily A,
members 6A and 4E
11q12.1 ~10% Cellular signaling
(Adapted from Tanzi 2012, Cold Spring Harb Perspect Med 2012;2:a006296)
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2.3 ENVIRONMENTAL RISK FACTORS
Addition to the genetic components, several environmental factors have been shown to
modify the risk of AD (Table 4). The risk of AD has been reported to be higher among
women than men (Tang et al., 1996). This might not only be due to longer life spans of
women but also to the reduction in the oestrogen levels after menopause. Oestrogens have
been shown to exert neuroprotective effects, and thus the decreased oestrogen levels might
lead to reduced neuroprotection and predispose the women to dementia (Tang et al., 1996).
Several diseases and their antecedents are recognized as AD risk factors. Cerebrovascular
diseases such as large cortical infarcts, single strategically placed infarcts, multiple small
infarcts, cerebral hemorrhage, cortical changes due to hypoperfusion, white matter changes
and vasculopathies, are all conditions known to increase the risk of dementia in general
(Mayeux and Stern, 2012). In addition, elevated blood pressure during middle age has been
associated with late-life cognitive impairment, suggesting that mid-life hypertension
augments the risk of dementia later in life (Kilander et al., 2000; Kivipelto et al., 2002). Type
II diabetes has been postulated approximately to double the risk of AD (Luchsinger et al.,
2001; Peila et al., 2002). It has been suggested that hyperinsulinemia present in type II
diabetes disrupts A clearance by providing a competitive substrate to IDE and this results
in decreased degradation and the gradual accumulation of A (Farris et al., 2003).
Furthermore, obesity, excess adipose tissue and type II diabetes are believed to be risk
factors e.g. the common metabolic and inflammatory factors including adiponectin, leptin,
resistin, tumor necrosis factor  (TNF-) and interleukin 6 (IL-6) associated with these
conditions may, in turn, affect the risk of AD (Trujillo and Scherer, 2005; Yu and Ginsberg,
2005). Individuals with a history of traumatic brain injury (TBI) have been shown to be at
an augmented risk of AD. The direct link between TBI and AD has been revealed by both
human post-mortem and experimental studies showing that A and tau pathologies are
increased after brain injury (Stone et al., 2002; Smith et al., 2003).
There are also protective factors that decrease the risk of AD. Cognitive reserve resulting
from a high educational level or engagement in mental, social and other productive
activities are associated with a decreased risk of AD (Qiu et al., 2001; Wang et al., 2002). In
addition to mental activity, physical activity has also been shown to reduce the risk of AD
(Rovio et al., 2005). This is supported by animal experiments which have indicated that
physical exercise enhances learning, brain plasticity and promotes brain vascularization
(van Praag et al., 1999; Cotman and Berchtold, 2002; Black et al., 1990). There are also
dietary factors influencing AD risk. A high intake of cholesterol and trans-unsaturated fats
augments the risk whereas consumption of unsaturated fats and fish or omega-3- fatty
acids has been associated with a decreased risk of AD (Sparks et al., 2000; Morris et al.,
2003). A Mediterranean diet and moderate red wine consumption have been postulated to
be able to reduce the risk of AD (Scarmeas et al., 2006; Vingtdeux et al., 2008).
13
Table 4. Environmental factors that modify the risk of AD
Antecedent Direction Possible mechanism
Cardiovascular disease Increased Parenchymal destruction
Strategic location
Increased A deposition
Smoking Increased Cerebrovascular effects
Oxidative stress
Hypertension Increased and decreased Microvascular disease
Type II diabetes Increased Cerebrovascular effect
Insulin and A compete for clearance
Obesity Increased Increased risk of type II diabetes,
inflammatory
Traumatic brain injury Increased Increased A and APP deposition
Education Decreased Provides cognitive reserve
Leisure activity Decreased Improves lipid metabolism, mental stimulation
Mediterranean diet Decreased Antioxidant, anti-inflammatory
Physical activity Decreased Activates brain plasticity, promotes brain
vascularization
(Adapted from Mayeux and Stern, 2012, Cold Spring Harb Perspect Med 2012;2:a006239)
2.4 MOLECULAR MECHANISMS OF -AMYLOID PATHOLOGY
2.4.1 A production
2.4.1.1 Amyloid cascade hypothesis
The exact series of molecular events in AD pathology has so far remained elusive, but the
so-called amyloid cascade hypothesis is now widely accepted and it offers a broad
framework to explain AD pathogenesis (Figure 4) (Hardy and Allsop, 1991). This
hypothesis was published over two decades ago and it states that accumulation of A is the
primary event in AD, which triggers the downstream events observed in the disease. In
FAD, causative mutations in APP, PSEN1 or PSEN2 genes and in LOAD, deficits in A
degradation and clearance lead to accumulation of A. The elevation of A levels leads to
the formation of A oligomers, especially from A42 species and deposition into plaques.
 oligomers display toxic effects on synapses. Simultaneously, A induces inflammatory
responses in astrocytes and microglia. These events are followed by oxidative stress,
induced by alteration in neuronal ionic homeostasis. This, in turn, alters the kinase and
phosphatase activities which then catalyze the hyperphosphorylation of tau, forming PHF
and NFTs. Ultimately, these events cause synaptic damage and neuronal loss leading to
dementia.
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The lack of details in amyloid cascade hypothesis has attracted some criticisms and it has
been updated and revised after the original publication (Selkoe, 2000). The amyloid cascade
hypothesis has also been challenged by several other hypotheses. One of these is the dual
pathway hypothesis, which states that the accumulation of A and tangle formation occur
in parallel but independently lead to neuronal loss and dementia (Small and Duff, 2008).
Figure 4. Amyloid cascade hypothesis. According to this hypothesis, increased A levels, due to either
augmented production or reduced clearance, lead to downstream events. A starts to accumulate and
forms toxic oligomers, which disrupt synaptic function and activate microglia and astrocytes. These are
followed by an alteration in neuronal ionic homeostasis and in kinase as well as phosphatase activities
causing hyperphosphorylation of tau and then tangle formation. In summary, these phenomena lead to
widespread neurotransmitter deficits, neuronal dysfunction and loss and finally to dementia. (Adapted
from Hardy and Selkoe, 2002, Science 297:353-356)
Indeed, the relationship between A and tau has been a fundamental issue in AD research
and there has been a vigorous debate on whether tau has a causative role or whether it is a
byproduct of some disease process. In addition to AD, tau pathology is also observed in
other neurodegenerative diseases, such as frontotemporal dementias and Pick’s disease
(Iqbal et al., 2009). There is no genetic linkage between AD and MAPT (microtubule-
associated protein tau) gene encoding tau. However, mutations in this gene have been
shown to cause FTDP-17 (Frontotemporal dementia with Parkinsonism linked to
chromosome 17) (Hutton et al., 1998).
An often presented argument against the amyloid cascade hypothesis is that the number of
 plaques does not correlate well with the cognitive decline. Instead, there is a good
correlation between the progression of neurofibrillary pathology and the cognitive decline
in AD (Ingelsson et al., 2004). However, there is mounting evidence indicating that soluble
oligomers of A, but not monomers or insoluble fibrils, are responsible for synaptic
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dysfunction (Walsh and Selkoe, 2004). The cortical levels of soluble A have been shown to
correlate with the extent of synaptic loss and the cognitive symptoms (Lue et al., 1999;
McLean et al., 1999; Wang et al., 1999). Furthermore, studies with APP transgenic mice have
demonstrated that electrophysiological, neuroanatomical and behavioral abnormalities
occur long before the appearance of microscopically visible A deposits (Holcomb et al.,
1999; Hsia et al., 1999; Mucke et al., 2000). Soluble A oligomers isolated from AD brain
have been shown to be able to block the long-term potentiation (LTP) in wild-type mouse
brain slices,  while insoluble A plaques isolated from the same AD cortices did not unless
they were first dissolved to release the oligomers (Shankar et al., 2008).  In addition, soluble
 oligomers have been shown to inhibit hippocampal LTP, alter memory and learning
performance and disrupt synaptic glutamate uptake (Li et al., 2009). These studies
demonstrate the critical role of soluble A oligomers in A toxicity; this seems to be more
toxic than A deposited into plaques.
Furthermore, the fact that transgenic AD mice with progressive A deposition often do not
show clear neuronal loss has been used to criticize the amyloid cascade hypothesis (Irizarry
et al., 1997). However, there are several plausible explanations, such as species differences
in neuronal vulnerability and inflammatory mediators, and the relatively short duration of
 exposure. APP transgenic mice actually develop neuritic dystrophy and suffer a
synaptic loss over time, but perhaps 2-3 years, which is the typical lifetime of a laboratory
mouse, is too short a time to achieve A-induced neuronal death (Mucke and Selkoe, 2012).
The lack of human tau in APP transgenic mice may also be one explanation for the lack of
neuronal loss in AD mouse models. Indeed, the APP transgene has been shown to
accelerate NFT formation in APP/tau double transgenic mice (Lewis et al., 2001).
The connection between A and tau has been extensively studied. Neurons expressing
either mouse or human tau have been reported to degenerate in the presence of fibrillar A,
while tau-depleted neurons were resistant to degeneration (Rapoport et al., 2002). Tau is
required in addition to A to impair axonal transport, and on the other hand, a reduction in
tau levels has conferred protection against defects in A-induced axonal transport (Vossel
et al., 2010). Moreover, reduced endogenous tau levels have been shown to prevent
behavioral deficits in human APP transgenic mice, without decreasing high A levels
(Roberson et al., 2007). Finally, a recent study revealed that A dimers extracted from the
brain of AD patients induce hyperphosphorylation of tau, disrupt the microtubule
cytoskeleton leading to neuritic dystrophy (Jin et al., 2011). There are several lines of studies
indicating that accumulation of A precedes neurofibrillary pathology, but also that tau is
needed to mediate the A toxicity in AD.
2.4.1.2 Tau hyperphosphorylation
Tau protein is encoded by the MAPT gene located at chromosome 17. More than 30
mutations in MAPT gene have been detected in frontotemporal dementia with
parkinsonism (Goedert and Jakes, 2005). However, mutations in the MAPT gene  do  not
associate with AD. Tau protein is a member of the microtubule-associated proteins (MAPs)
(Mandelkow and Mandelkow, 2012). The tau protein is present mainly in the axons of the
CNS and alternative splicing of MAPT leads to the generation of six tau isoforms (Goedert
et al., 1989). Tau is able to interact with tubulin and stabilizes microtubules, which are
protein polymers of the cytoskeleton. The microtubules stabilize the cell shape, participate
in mitosis and function as tracks for intracellular transport of vesicles and organelles by
motor proteins. The interaction of tau with tubulin is regulated by the phosphorylation
status of tau (Iqbal et al., 2009). The balance between the activities of the protein kinases
and the protein phosphatases, in turn, regulates the phosphorylation status of tau.
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In AD, tau is hyperphosphorylated and it becomes detached from microtubules leading to
microtubule disruption. Hyperphosphorylated tau is insoluble and it self-associates into
paired helical filaments and finally to NFTs. Currently, a total of 39 serine or threonine
phosphorylation sites have been identified in tau protein isolated from AD brain (Hanger et
al., 2007). Several kinases are known to be involved in phosphorylation of tau, including
glycogen synthase kinase-3 (GSK-3), cyclin dependent protein kinase-5 (cdk5), protein
kinase A (PKA), calcium and calmodulin-dependent protein kinase-II (CaMKII), casein
kinase-1 (CK-1), mitogen-activated protein (MAP) kinase ERK 1/2, and stress-activated
protein kinases (SAPKs) (Iqbal et al., 2005). There are also several tau phosphatases in the
brain. However, protein phosphatase 2A and 1 (PP-2A and PP-1, respectively) are
responsible for more than 90% of the serine/threonine protein phosphatase activity
occuring in mammalian cells. The activities of these phosphatases have been shown to be
reduced by ~20% in AD brain, which possibly contributes to tau pathology in AD (Gong et
al., 1995). Under normal conditions, phosphorylated tau contains 2–3 mol of phosphate/mol
of the protein, but in AD, phosphorylated tau has at least three to fourfold more
phosphate/mol of protein (Kopke et al., 1993).
2.4.1.2 APP trafficking, processing and function
 depositions are major neuropathological hallmarks of AD and they distinguish AD
from other forms of dementia. A peptide contains 37-43 amino acid residues, it has a
molecular weight ~4 kDa. It is generated from its precursor protein APP (Selkoe, 2001). APP
is a part of highly conserved protein family that includes mammalian amyloid precursor-
like protein 1 and 2 (APLP1 and APLP2) (Wasco et al., 1993). It is a type-I transmembrane
protein and alternative splicing of APP gives rise to the formation of three common
isoforms. The shortest APP695 is predominantly expressed in neurons whereas APP751 and
770 isoforms are ubiquitously expressed (Selkoe, 2001). Within the ectodomain of APP751
and 770 isoforms, one can find a Kunitz-type inhibitor (KPI) domain which is serine
protease inhibitor domain, capable of modulating the processing of APP (Vetrivel and
Thinakaran, 2006).
APP trafficking
In neurons, APP is produced in large quantities but it is rapidly metabolized (Lee et al.,
2008). After its translation, APP is targeted to the constitutive secretory pathway and
during its transport through the endoplasmic reticulum (ER) and Golgi in secretory vesicles
to plasma membrane, it undergoes several post-translational modifications such as N- and
O-linked glycosylation, and phosphorylation and tyrosine sulphation at different sites
(Figure 5) (Thinakaran and Koo, 2008). A proportion of APP is also transported directly to
the endosomes.  It has been postulated based on cell culture models that the majority of
APP is localized in the Golgi apparatus and in the trans-Golgi network (TGN) and only a
small portion reaches plasma membrane (Vetrivel and Thinakaran, 2006). From the plasma
membrane, APP is rapidly reinternalized in clathrin-coated pits because it possesses
“YENPTY” internalization motif which is located in the carboxy terminus (Lai et al., 1995).
After endocytosis, a fraction of APP is recycled back to the cell surface, while a significant
amount of internalized APP is degraded in lysosomes (Haass et al., 1992).
In AD, the intracellular trafficking of APP in neurons plays a pivotal role. A is mainly
secreted from distal axons and synapses (Lazarov et al., 2002). However, due to a complex
morphology  of  neurons,  the  precise  subcellular  sites  of  APP  processing  in  neurons  by  -
and -secretase is not known as well as in non-neuronal cells (Haass et al., 2012). APP is
found in somas, in dendrites as well as in axons and because of the polarized nature of
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neurons, its cellular transport differs from other cells. APP is transported from ER to Golgi
and TGN in a similar manner in neurons and in non-polarized cells. However, in neurons,
APP is transported from TGN to axons and dendrites in the post-Golgi transport vesicles
(Kins et al., 2006). APP is delivered to axons via a fast axonal transport system (Sisodia et
al., 1993), which uses kinesin-1 as its microtubule motor protein. The axonal delivery of
APP possesses one of the fastest transport velocities measured in cultured cells and also
significant retrograde transport has been observed (Kaether et al., 2000).
Figure 5. Schematic presentation describing the intracellular trafficking of APP. After translation, APP
molecules (black bars) are directed to the constitutive secretory pathway, in which they mature (1). When
APP reaches the plasma membrane, it is rapidly internalized (2) and consequently targeted via endocytic
and recycling organelles to TGN or to the plasma membrane (3). A small proportion is also targeted to
lysosomal degradation. Non-amyloidogenic -secretase cleavage of APP takes place mainly at the cell
surface while amyloidogenic -secretase cleavage of APP occurs primarily in endosomes. (Reproduced from
Thinakaran and Koo, "Amyloid precursor protein trafficking, processing, and function", Journal of Biological
Chemistry, 2008, vol. 283, pp. 29615-29619. © the American Society for Biochemistry and Molecular
Biology)
APP processing
APP is proteolytically processed at different subcellular sites by three enzymes called -, -,
and -secretase. There are two distinct pathways in APP processing: amyloidogenic and
non-amyloidogenic pathways (Figure 6) (Vetrivel and Thinakaran, 2006). A is generated in
amyloidogenic pathway, which is initiated by -secretase (BACE1) cleavage leading to the
formation of soluble ectodomain part of APP (sAPP) and carboxy-terminal fragment
CTF or C99). Subsequently, C99 is cleaved by -secretase, which releases the A peptide
to be secreted out from the cells and the APP intracellular domain (AICD) dispatched to the
cytosol (Vetrivel and Thinakaran, 2006). In the non-amyloidogenic pathway, APP is
consecutively cleaved by - and -secretases. The cleavage site of -secretase is located in
the middle of A region preventing A production; -cleavage generates the soluble APP
(sAPP) domain and CTF (or C83). Subsequently, -secretase liberates the truncated A
peptide called p3 and AICD. In non-neuronal cells, approximately 10% of APP is processed
through amyloidogenic pathway leading to generation of A. However, in neurons,
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amyloidogenic processing of APP has been suggested to be more common because of the
greater abundance of BACE1 (Haass et al., 2012).
BACE1 is  the  only  -site  cleaving  enzyme of  APP since  its  knockout  totally  blocks  the  -
secretase activity and inhibits A generation (Roberds et al., 2001). APP has been shown to
be internalized from plasma membrane via clathrin-dependent endocytosis to endosomes,
where the pH is optimal (pH ~4.5) for -secretase activity. Indeed, BACE1 cleavage of APP
has been postulated to occur in endosomes since it has been shown that APP and BACE1
have to encounter each other in this compartment in order to initiate the A production
(Vassar et al., 1999; Golde et al., 1992).
Figure 6. Proteolytic processing of APP through non-amyloidogenic or amyloidogenic pathway. In non-
amyloidogenic pathway, processing of APP protein is initiated by -secretase, which cleaves APP within the
 domain resulting the generation of sAPP and C83. Amyloidogenic pathway, in turn, is initiated by -,
secretase, which cleaves APP resulting in the formation of sAPP and C99. Subsequently, C83 and C99 are
cleaved by -secretase, which liberates p3 and A, respectively. (Adapted from Thinakaran and Koo, 2008,
Journal of Biological Chemistry 283:29615-29619)
-Secretase is a large enzyme complex consisting of four different integral membrane
proteins: presenilin (PS) 1 or PS2, presenilin enhancer 2 (PEN-2), anterior pharynx defective
1(APH-1) and nicastrin (NCT). PS1 and PS2 contain nine transmembrane domains (TMDs)
and two crucial aspartyl residues within TMDs 6 and 7, which are part of the catalytic
domain of the aspartyl protease activity of the -secretase complex (Wolfe et al., 1999). The
presence of PEN-2 is necessary to stabilize the PS fragments in the -secretase complex and
it facilitates PS endoproteolysis into its active heterodimeric state. NCT has been postulated
to serve as a -secretase receptor, but its precise function is unclear. NCT and APH-1 form
an initial scaffold of the -secretase complex in which PS1 (or PS2) and PEN-2 subsequently
bind (St George-Hyslop and Fraser, 2012). The intramembrane cleavage of APP by -
secretase is not limited to a single site, but it appears that -secretase cleaves its substrates
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several times in a stepwise manner within the transmembrane domain. These cleavage sites
in APP are called -, -, and -sites; they are separated by approximately three amino acids
(Figure 7). Furthermore, the -site cleavage is not precise and it seems it can occur in a
region anywhere between amino acids 37 and 43 of the A domain (Weidemann et al.,
2002). If -secretase cleavage initiates the -cleavage after amino acid 49, the cleavage
proceeds in three amino acid steps producing A40. Instead, if proteolysis of APP begins by
the -cleavage after amino acid 48, this leads to the production of A42. Non-steroidal anti-
inflammatory drugs (NSAIDs) have been shown to modulate the -secretase processing of
APP by favoring the production of the less toxic A40 form. Thus, modulation of -
secretase possesses a therapeutical potential in being able to selectively prevent A42
generation (Schenk et al., 2012). In addition to APP, there are several other -secretase
substrates. The most important of these is Notch1, which is involved not only in
embryogenesis and development, but also in the differentiation of immune and stem cells
(van Es et al., 2005). Because of these essential functions of Notch1, PS knockout mice are
embryonically lethal (Herreman et al., 1999). Altogether, there are tens of -secretase
substrates and many of them are involved in synaptic functions, neurite outgrowth and cell
adhesion (Haapasalo and Kovacs, 2011). Due to the crucial role in A production, the -
secretase has been considered as a potential drug target. However, the large number of -
secretase substrates with vital functions has meant that the therapeutic inhibition of -
secretase is rather challenging.
Figure 7. Schematic presentation of sequential processing of APP by -secretase. It has been postulated
that -secretase processes APP at -, -, and -sites separated by approximately three amino acids. There
are two main A production lines. A42 generation is initiated by -cleavage after amino acid 48. This is
followed by -site cleavage after amino acid 45 and -site cleavage after amino acid 42. A40 generation,
in turn, begins with -cleavage after amino acid 49. This is then followed by -site cleavage after amino
acid 46 and -site cleavages after amino acids 43 and 40. The known -secretase cleavage sites and the
resulting products are indicated in the transmembrane domain of APP. (Reproduced from Steiner et al.,
"Intramembrane Proteolysis by -secretase", Journal of Biological Chemistry, 2008, vol. 283, pp. 29627-
29631. © the American Society for Biochemistry and Molecular Biology)
-Secretase cleavage of APP occurs predominantly at the plasma membrane (Haass et al.,
2012). In contrast, to BACE1 and -secretase, there is no single -secretase enzyme, but -
secretase activity is shared by a set of a disintegrin and  metalloprotease (ADAM) family
members. However, there is some evidence that ADAM10 is responsible for constitutive -
secretase activity in neurons (Kuhn et al., 2010). In addition to APP, there are a number of
substrates of -secretases, including Notch receptors and ligands, TNF, IL-6 receptor and
several other type I transmembrane proteins. Similar to APP, -secretase cleavage of the
other substrates releases their extracellular domain (Haass et al., 2012). BACE1 is abundant
in neurons favoring the amyloidogenic pathway, while the non-amyloidogenic pathway is
predominant in all other cell types. Since -secretase cleavage of APP prevents A
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production, the upregulation of -secretase activity as a way to elevate non-amyloidogenic
processing has a potential therapeutic value (Postina et al., 2004).
APP function
The investigation of the physiological role of APP has been challenging because its complex
proteolytical cleavage produces several peptides with different functions. Furthermore,
APP-like proteins (APLPs) with overlapping functions and similar proteolytical processing
makes it even more complicated. However, APP has been shown to possess a number of
physiological roles, but perhaps the best established function is its trophic role. APP has
been shown to affect the growth of fibroblasts (Saitoh et al., 1989) and to stimulate neurite
outgrowth (Hoe et al., 2009). Furthermore, expression of APP is upregulated during
neuronal maturation and differentiation (Hung et al., 1992). Another well-established
function of APP is its involvement in cell adhesion. The RHDS motif in APP appears to
promote the cell adhesion and this region is believied to function in an integrin-like manner
(Ghiso et al., 1992). APP has also been shown to colocalize with integrins on the surface of
axons and at sites of adhesion (Yamazaki et al., 1997). APP and particularly the AICD
fragment have been connected also to intracellular signalling and gene transcription (Cao
and Sudhof, 2004). The “YENPTY” motif in the AICD fragment can interact with adaptor
proteins, such as FE65, which contain a phosphotyrosine-binding domain. Binding of FE65
to AICD has been speculated to lead to their translocation to the nucleus and than to the
formation of a trimeric complex together with the histone acetyltransferase Tip60. This
complex, in turn, has been claimed to be involved in the transcriptional regulation of genes
such as APP, BACE1, Tip60 and GSK-3 (von Rotz et al., 2004).
2.4.1.3 BACE1
In A production, -Site  APP Cleaving Enzyme 1 (BACE1) is the first and also the rate-
limiting enzyme. In the late 1990’s, five research groups independently identified the same
aspartyl protease as being the enzyme responsible for -secretase activity (Vassar et al.,
1999; Hussain et al., 1999a; Sinha et al., 1999; Yan et al., 1999; Lin et al., 2000). The enzyme
was named BACE1 to distinguish it from BACE2, a homologue with very low expression in
the brain. Other names such as memapsin and aspartyl protease 2 (Asp2) have been used.
BACE1 is highly expressed in the pancreas and in the brain, particularly in the cortex
(Vassar et al., 1999). Under normal conditions, BACE1 is mostly expressed by neurons.
However, it has been shown that in different stress conditions BACE1 levels increase
drastically and it is expressed also in astrocytes, which may exacerbate A production
(Hartlage-Rubsamen et al., 2003; Blasko et al., 2004; Hiltunen et al., 2009).
BACE1 protein levels and -secretase activity have been shown to be higher in the frontal
and temporal cortices in AD brain than in healthy controls (Fukumoto et al., 2002;
Holsinger et al., 2002; Li et al., 2004; Tyler et al., 2002; Yang et al., 2003). Since most of the
studies have not observed any elevations in the levels of BACE1 mRNA in AD brain, the
increase in BACE1 protein levels has been proposed to be associated with post-
transcriptional events (Holsinger et al., 2002; Johnston et al., 2005). Indeed, several results
suggest that BACE1 is a stress-response protein; BACE1 protein levels but not mRNA levels
are increased by energy deprivation (Velliquette et al., 2005), oxidative stress (Tamagno et
al., 2002), hypoxia (Zhang et al., 2007), ischemia (Wen et al., 2004), apoptosis (Tesco et al.,
2007), and traumatic brain injury (Blasko et al., 2004). The 5’UTR of BACE1 mRNA is long
and GC-rich, containing extensive secondary structures and three upstream open reading
frames (uORFs) leading to inefficient translation under normal conditions. It has been
shown that energy deprivation increases the phosphorylation of eukaryotic translation
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initiation factor 2 (eIF2) at Ser51 (O'Connor et al., 2008). The 5’UTR of BACE1 mRNA is
long and GC-rich containing extensive secondary structures and three upstream open
reading frames (uORFs) leading to inefficient translation under normal conditions. When
stress is present, however, increased phosphorylation of eIF2 enables the ribosome to scan
through the 5’UTR of BACE1 and to start the translation, and this will increase the BACE1
expression (O'Connor et al., 2008).
BACE1 is initially synthesized in the ER as a zymogen. This immature precursor protein
(proBACE1) is 501 amino acids long and it contains an N-terminal signal peptide (residues
1-21), followed by a pro-domain (residues 22-45) (Figure 8). The signal peptide and pro-
domain are removed by furin in Golgi, and thus the mature BACE1 begins at residue Glu46
(Bennett et al., 2000). After the pro-domain, there exists a long protease domain containing
two aspartic protease active site motifs, DTGS (residues 92-95) and DSGT (residues 289-
292). A single transmembrane domain (residues 455-480) and a short cytosolic domain are
located in the C-terminus of BACE1. BACE1 is co-translationally glycosylated at four
asparagine residues in the lumen of ER (Haniu et al., 2000). Simultaneous transient
acetylation at seven lysine residues increases the stability of BACE1 and promotes its
trafficking through the secretory pathway (Costantini et al., 2007). Subsequently, the
addition of complex carbohydrates occurs in the Golgi compartment (Capell et al., 2000).
This maturation process approximately doubles the catalytic activity of BACE1 as
compared to immature BACE1. In addition, the cytoplasmic tail of BACE1 undergoes post-
translational modifications. Palmitoylation of a cluster of three cysteine residues at C-
terminus regulates the targeting of the protein to the lipid rafts (Benjannet et al., 2001).
There are also six luminal cysteine residues that form three intramolecular disulfide bonds
(Haniu et al., 2000).
Figure 8. Schematic presentation of BACE1 protein structure. BACE1 is a 501 amino acid long protein
containing a signal peptide (SP, residues 1-23) and a pro-domain (Pro, residues 23-48) at the N-terminus.
The protease domain contains two consensus motifs characteristic of an aspartyl protease active site
(DTGS and DSGT, residues 92-95 and 289-292, respectively). After them, there are a single
transmembrane domain (TM, residues 454-478) and a short cytosolic domain (CD, residues 478-501).
Glycosylation and phosphorylation sites are indicated by N and S letters, respectively. Three disulfide
bonds (S–S) connect amino acids 216–420, 278–443 and 330–380. (Adapted from Vassar et al., 2009, J.
Neurosci., 29:12787–12794)
Mature BACE1 is rather stable having a half-life of approximately nine hours and it cycles
between various compartments of the secretory pathway (Cole and Vassar, 2007). From the
TGN, it is transported to the cell surface where it becomes enriched as dimers within lipid
rafts. Alternatively, BACE1 can be transported from TGN directly to the endosomes. The
intracellular trafficking of BACE1 is mainly regulated by targeting signals in the cytosolic
domain (Pastorino et al., 2002). Internalization from the plasma membrane and targeting to
endosomes is dependent on the C-terminal di-leucine motif (DISLL, residues 496-500).
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Phosphorylation at serine 498 is sufficient for recycling BACE1 from the endosomes back to
TGN (Walter et al., 2001). The di-leucine motif in BACE1 binds to adaptor proteins called
Golgi-localized, -ear containing ADP ribosylation-binding factor (GGAs). GGA1, 2 and 3
are monomeric adaptor proteins, which bind proteins containing the di-leucine motif and
participate in their transport from Golgi to endosomes, and in the recycling pathway, from
endosomes to the TGN. In particular, GGA3 is also involved in the delivery of proteins
from the endosomes to the lysosomes (Puertollano and Bonifacino, 2004). All three
members of the GGA protein family participate in trafficking of BACE1, since RNAi
mediated  depletion  of  any  of  these  factors  leads  to  a  significant  re-distribution  of  BACE1
(He et al., 2005). GGA1 is involved in the retrograde transport of phosphorylated BACE1
from endosomes to TGN (He et al., 2005; Wahle et al., 2005). In addition to GGA1, the
retromer protein complex is known to mediate the retrograde transport of BACE1 (Finan et
al., 2011). GGA3, in turn, is known to participate in sorting BACE1 from endosomes to the
lysosomes for degradation. In addition, ubiquitination of BACE1 has been shown to be
important for trafficking (Kang et al., 2010). Ubiquitin is a small (8.5 kDa) regulatory signal
protein which modifies the intracellular localization of its substrates. The attachment of the
lysine 48 -linked polyubiquitin chain directs proteins to proteosomal degradation whereas
lysine 63-linked ubiquitination is a signal for lysosomal degradation (Kang et al., 2010;
Mukhopadhyay and Riezman, 2007). Furthermore, ubiquitination at the C-terminal lysine
501 residue is a recognition signal independent of the di-leucine motif for GGA3 to target
BACE1 to the lysosomal degradation route (Kang et al., 2012). BACE1 cleavage has been
postulated to occur in endosomes since this compartment has an optimal pH (pH ~4.5) for
-secretase activity (Koo and Squazzo, 1994). In contrast to APP, BACE1 has been shown to
be internalized from plasma membrane to endosomes in a clathrin-independent manner. A
recent study has shown that internalization of BACE1 is also affected by a small GTPase
ADP ribosylation factor 6 (ARF6) (Sannerud et al., 2011). ARF6 is required to mediate the
sorting of BACE1 to Rab5-positive early endosomes where -site cleavage of APP occurs
(Sannerud et al., 2011).
The fact that BACE1 has other substrates in addition to APP, such as APLP1 and 2 (Li et al.,
2004; Pastorino et al., 2004), has prompted several groups to investigate physiological
functions of BACE1 in normal conditions. Initial studies revealed no adverse effects in
BACE1 knockout (BACE1-/-) mice on embryonic development or morphology, physiology,
biochemistry and behavior of post-natal or adult mice (Roberds et al., 2001; Luo et al., 2001).
However, more detailed behavioral studies have reported abnormalities in cognitive and
emotional functions. In particular, these mice exhibited impairments in spatial and
reference memory as well as in temporal associative memory (Ohno et al., 2006), raising the
possibility that BACE1 is required for normal hippocampal memory processing. Molecular
studies have revealed that processing of APP by BACE1 is modulated by the neurite
growth inhibitor Nogo, which belongs to reticulon protein family and is a component of
myelin (He et al., 2004). Furthermore, BACE1 has been proposed to have a role in axonal
growth and brain development by regulating the myelination process (Willem et al., 2006).
Myelination and myelin sheath thickness is modulated by neuregulin-1 (NRG-1), which is a
BACE1 substrate. A deficiency of BACE1 in knockout mice has been shown to result in the
accumulation of unprocessed NRG1 and simultaneous hypomyelination (Willem et al.,
2006). In addition, low-density lipoprotein receptor related protein (LRP1) (von Arnim et
al., 2005), voltage-gated sodium channel 2 subunit (Nav2) (Kim et al., 2007; Wong et al.,
2005) and neuregulin-3 (Hu et al., 2008) are known to be BACE1 substrates that may affect
neuronal functions.
Since it is a fundamental player in  production, BACE1 has been intensively studied as a
potential therapeutic target. Small molecule inhibitors of BACE1 have been designed to
decrease the BACE1 activity and generation of A (Evin et al., 2011). However, the above-
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mentioned wide spectrum of BACE1 substrates complicates the design of BACE1 inhibitors
because of potential side effects arising from excessive inhibition or reduction of BACE1
function (Vassar et al., 2009). Thus, moderate BACE1 inhibition or combined but moderate
inhibition of both BACE1 and -secretase has been speculated as representing potentially
more viable treatment strategies for AD.
2.4.1.4 GGA3
The GGAs may be the best characterized factors involved in BACE1 intracellular
trafficking. They are monomeric adaptor proteins that are recruited to the TGN by the Arf-
GTPase. The GGA protein family consists of three members, which all include three
structural domains; VHS, GAT and GAE domains (Bonifacino, 2004). The VHS (Vps27, Hrs,
Stam) domain binds to its target protein which possess an acidic di-leucine motif (or
DXXLL, where X is any amino acid). The GAT (GGA and TOM) domain binds GTP-Arf
(GTP bound ADP-ribosylation factor). There is a hinge region between GAT and GAE
domains, which does not have significant sequence similarity among the GGAs, but which
recruits clathrin. GAE (-adaptin ear) domain, in turn, recruits adaptin and other proteins
necessary for packaging of transport vesicles (Bonifacino, 2004). GGA3 has been shown to
mediate targeting of BACE1 to the lysosomes for degradation and regulating the BACE1
levels (Tesco et al., 2007). The di-leucine motif that is present in BACE1 and in several other
transmembrane proteins (e.g. mannose 6-phosphate receptor) regulates endocytosis, as well
as lysosomal degradation (Bonifacino and Traub, 2003).
GGA3 has been shown to be a substrate for caspase 3, which under apoptotic conditions
cleaves GGA3. Therefore,  the targeting of BACE1 from endosomes to lysosomes is
inhibited, which results in increased A production (Tesco et al., 2007). It has been shown
in vitro that the RNAi-induced reduction of GGA3 protein levels impairs the degradation of
BACE1, leading to increased BACE1 activity and A generation (Tesco et al., 2007).
Moreover, GGA3 protein levels have been found to be reduced in AD temporal cortex and
these levels correlate inversely with BACE1 protein levels as compared to healthy controls
(Tesco et al., 2007).
Seladin-1, also known as 3-hydroxysterol-	24 reductase (DHCR24), has been shown to
indirectly affect the BACE1 levels. Seladin-1 protects neurons against oxidative stress
(Greeve et al., 2000). Sarajärvi et al. have shown that decreased Seladin-1/DHCR24 levels
contribute to caspase 3-mediated GGA3 depletion and hence increase the BACE1 levels and
activity under apoptotic conditions (Sarajärvi et al., 2009).
2.4.1.5 Ubiquilin-1
Ubiquilin-1, also known as PLIC-1 [protein linking IAP (integrin-associated protein) with
cytoskeleton-1], is encoded by the UBQLN1 gene consisting of 11 exons. Alternative
splicing of UBQLN1 leads to the generation of four different transcript variants (TVs). Two
common variants are full-length TV1 and TV2, which lacks exon 8. Furthermore, TV3 lacks
exons  2,  3  and  4  and  TV4  contains  only  exons  1,  2  and  3  and  a  unique  3’  end  (Lu  et  al.,
2009).
The association between genetic variation in UBQLN1 gene and AD was revealed by the
finding that intronic SNPs, UBQ-8i and rs2781002, which are downstream of exon 8
significantly increase the risk of AD (Bertram et al., 2005). The same study revealed that the
ratio of TV2:TV1 mRNA was significantly increased in AD brains as compared to control
subjects (Bertram et al., 2005). Despite the fact that the genetic association of UBQLN1 with
AD has been confirmed by several studies (Slifer et al., 2005; Kamboh et al., 2006; Golan et
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al., 2008), negative results have also been reported (Brouwers et al., 2006; Giedraitis et al.,
2009). However, a recent study revealed an overall decline in the ubiquilin-1 protein levels
in AD brain as compared to healthy controls, confirming the potential role of ubiquilin-1 in
AD pathogenesis (Stieren et al., 2011).
Ubiquilin-1 is involved in the regulation of subcellular trafficking, thus controlling the
levels, and degradation of several proteins. Ubiquilin-1 is a member of a highly conserved
group of ubiquitin-like proteins containing an ubiquitin-like domain (UBL) in the N-
terminus and ubiquitin-associated domain (UBA) in the C-terminus (Kleijnen et al., 2000;
Ko et al., 2002; Mah et al., 2000). The UBL domain interacts with the S5a component in the
19S subunit of the proteasome while UBA domain binds polyubiquitinated proteins. Thus,
the main function of these proteins is the targeting of ubiquitinated proteins for
proteosomal degradation. In addition, the central region of ubiquilin-1 contains conserved
asparagine- and proline-rich repeats (Asn-Pro-rich repeats), which mediate the interaction
with other proteins (Mah et al., 2000; Ficklin et al., 2005). Asn-Pro-rich repeats have been
shown to interact with the EH [EPS15 (epidermal growth factor substrate 15) homology]
domain, which is found in several of the proteins involved in endocytosis and vesicle
sorting, suggesting that ubiquilin-1 participates in the regulation of vesicular trafficking
(Mah et al., 2000).
Ubiquilin-1 was originally described as a protein which interacted and stabilized the
presenilins (Mah et al., 2000). Subsequent studies have also confirmed the role of ubiquilin
as a presenilin-stabilizing protein (Massey et al., 2004; Viswanathan et al., 2011). Ubiquilin-1
has been shown to affect also presenilin ubiquitination and degradation (Massey et al.,
2004; Massey et al., 2005). In addition to presenilin, ubiquilin-1 has been shown to affect
APP. It has been shown to regulate the maturation of APP, since RNAi-mediated
downregulation of ubiquilin-1 accelerated the maturation and intracellular trafficking of
APP in both neuronal and non-neuronal cells (Hiltunen et al., 2006). In line with this,
overexpression of ubiquilin-1 has been shown to increase the A42:A40 ratio in HeLa cells
and downregulation of ubiquilin-1 rendered cells more susceptible to APP-induced cell
death (Stieren et al., 2011).
Ubiquilin-1 has been shown to be localized in ER where misfolded or damaged proteins are
transported for proteasomal degradation (Lu et al., 2009; Ko et al., 2002). Accumulation of
misfolded proteins in ER leads to ER-stress and the unfolded protein response (UPR),
which may play a role in AD pathogenesis (Uehara et al., 2006). It has been shown that
ubiquilin-1 augments the UPR by attenuating the induction of UPR-inducible genes CHOP
(C/EBP homologous protein), BiP (binding immunoglobulin protein), and PDI (protein
disulfide isomerase) during ER- and hypoxic stress (Lu et al., 2009; Ko et al., 2002).
Furthermore, alleviation of ER-stress by ubiquilin-1 led to augmented cell survival (Lu et
al., 2009).
In accordance with ubiquilin-1 function as a chaperone protein, there has been reported to
be a relationship between ubiquilin-1 and several other proteins playing a significant role in
the CNS. Ubiquilin-1 has been shown to interact with -aminobutyric acid A receptor
(GABAAR)  subunits  and  to  affect  the  number  GABAA receptors in the plasma membrane
(Bedford et al., 2001), trafficking and possibly the proteasomal degradation of GABAAR
(Saliba et al., 2008). Ubiquilin-1 has also been shown to decrease the number of nicotinic
acetylcholine receptor (nAChR) subunits on the cell surface (Ficklin et al., 2005). In
summary, these data suggest that ubiquilin-1 may affect the activity-dependent
neurotransmission by regulating the receptor levels on the cell surface.
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2.4.2 A degradation and clearance
2.4.2.1 A-degrading enzymes
The accumulation of A in the brain parenchyma has been hypothesized to be the ultimate
reason for the development of AD. While increased production of A or increased ratio of
42 to A40 is the underlying molecular mechanism in the familial, autosomal dominant
form  of  AD,  it  has  been  postulated  that  the  more  common  late-onset  form  of  the  disease
may be attributable to defects in A clearance or degradation (Tanzi et al., 2004). This has
been supported by the recent finding from a metabolic labeling study, which revealed an
impaired A clearance in the CNS of late-onset AD patients as compared to controls. The
production rate of A was at the same level in both groups (Mawuenyega et al., 2010). A is
continuously produced and eliminated and in simple terms, the accumulation of A
occurring over decades can be determined as a net result of A production versus
clearance. While A is generated from one source and this process is well characterized, the
elimination of A involves several parallel processes with partly unclear molecular
mechanisms; proteolytic degradation, cell-mediated clearance, passive and active transport,
in addition to the aggregation and deposition of A into insoluble aggregates (Saido and
Leissring, 2012). Furthermore, proteolytic degradation of A alone is mediated by a large
number of proteases (Table 5) with a variety of characteristics and different regional,
cellular and subcellular localizations.
The most extensively studied A-degrading enzymes are NEP and IDE. NEP is a member
of the zinc-metalloprotease family (Hersh and Rodgers, 2008). It is a type II membrane-
associated protease with its catalytic site exposed to the extracellular side of membranes,
which is ideally suited for the degradation of extracellular peptides such as A. NEP is
almost exclusively expressed in neurons and it is transported from the soma to presynaptic
terminals (Fukami et al., 2002). A levels have been shown to correlate inversely with the
enzymatic activity of NEP. Neprilysin degrades only monomeric A. In vitro studies have
revealed that NEP is able to degrade the oligomeric forms of synthetic A, but not the
naturally secreted A oligomers isolated from the cell culture medium (Kanemitsu et al.,
2003; Leissring et al., 2003). In in vivo studies, eightfold overexpression of NEP in mice
resulted in ~90% reduction of monomeric A levels and a complete prevention of -
amyloid plaque formation (Leissring et al., 2003). However, despite the enormous
reduction of monomeric A levels, the overexpression of NEP did not alter the oligomeric
 levels and failed to reverse the learning and memory deficits present in the transgenic
mouse strain used in that study (Meilandt et al., 2009).
Like NEP, IDE is also a zinc metalloprotease. It is predominantly expressed in neurons and
exclusively  degrades monomeric A. In contrast to NEP, IDE is localized in a wide variety
of cellular compartments. IDE is most abundant in cytosol and mitochodria, but it has been
reported to be present, at least to some extent, in peroxisomes, endosomes and in ER
(Falkevall et al., 2006; Leissring et al., 2004; Kuo et al., 1994; Carpenter et al., 2010). IDE is
also present in the extracellular space, both in secreted (Qiu et al., 1998) and cell-associated
forms (Vekrellis et al., 2000). The precise underlying mechanisms of IDE secretion have
remained unclear, partly because there is no classical signal peptide sequence in IDE and
thus it is exported via an unconventional secretory pathway (Zhao et al., 2009). The most
convincing evidence supporting the role of IDE in A degradation has emerged from in
vivo studies, which have shown that IDE knockout mice exhibit significantly increased A
levels in the brain. Furthermore, the A levels in the brain of heterozygous IDE -/+ mice
were intermediate between IDE knockout and wild-type control mice (Farris et al., 2003).
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Table 5. Proteases implicated in the degradation of A
Max. relative
brain A levels in
KO micea
 substratesb
Type Protease 40 42  Oligom
eric
Fibrils Subcellular localizationc
Metallo NEP 2.0 2.0  Synth. No Ex, ER, G
NEP2 1.3 1.6 Ex, ER, G
MMEL Ex, ER, G
ECE1 1.3d 1.3d Ex, ER, G, Endo
ECE2 1.3 1.3 Ex, ER, G, Endo
ACE N.S. N.S. Ex, ER, G
MMP2 1.2 1.3 Yes Ex, ER, G
MMP9 N.S. 1.3 Yes Ex, ER, G
MMP14/MT1-MMP Yes Ex, ER, G
CD147/EMMPRIN Ex, ER, G, Endo
IDE 1.6 1.4  No No Ex, ER, Endo, Lyso, Mito
Serine Plasmin N.S. N.S.  Natural Yes Ex, ER, G
Acylpeptide hydrolase  Natural Ex, Cyto
Myelin basic protein Yes Ex, ER, G
Aspartyl Cathepsin D N.S. 3.0 Yes Endo, Lyso
BACE1 0.0 0.0 Endo, Lyso
BACE2 N.S. N.S. No Endo, Lyso
Cysteine Cathepsin B N.S. N.S. Yes Ex, Endo, Lyso
Threonine Proteasome Cyto
Other Catalytic antibodies -
aData reflect the maximum published values for endogenous cerebral A levels in mice lacking both copies
of the individual enzymes, expressed as relative levels compared to wild-type controls. KO, knockout;
N.S., no significant difference.
bAggregated forms of A known to be degraded by the individual enzymes. Synth, synthetic A oligomers;
Natural, naturally secreted A oligomers.
cEx, extracellular space; ER, endoplasmic reticulum; Endo, endosomes; Lyso, lysosomes; Mito,
mitochondria; Cyto, cytosol.
dEffect induced by deletion of one copy of ECE1.
(Adapted from Saido and Leissring, 2012, Cold Spring Harb Perspect Med 2012;2:a006379)
2.4.2.2 A clearance
In addition to proteolytic degradation, another major pathway in A elimination is
receptor-mediated clearance (Tanzi et al., 2004). The most widely studied and best-
characterized receptor involved in A clearance is low-density lipoprotein receptor-related
protein 1 (LRP1). LRP1 is a member of the low-density lipoprotein receptor (LDLR) family
consisting of cell surface receptors that internalize extracellular ligands, such as APOE, for
lysosomal degradation (Hussain et al., 1999b; Herz and Strickland, 2001). LRP1 is abundant
in neuronal cell surfaces and also expressed by glial cells surrounding the A plaques
(Christie et al., 1996). It has been shown to regulate A trafficking into the cell and from the
brain to blood circulation through the blood brain barrier (BBB) (Zlokovic, 2004). Once A
is internalized into the cell, it can be targeted to lysosomal degradation or transcytosed via
BBB to the bloodstream, which transport it to the peripheral sites of degradation e.g. kidney
or liver. LRP1 can bind to A directly or indirectly via its ligands such as 2-macroglobulin,
receptor-associated protein (RAP) and APOE (Deane et al., 2008; Narita et al., 1997;
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Kanekiyo and Bu, 2009; Bu, 2009). From these, APOE is the best-characterized A
chaperone. APOE isoforms have been shown to differentially affect A clearance, so that
APOE4 results in slower clearance as compared to APOE3 or APOE2 (Castellano et al.,
2011).
As an alternative to peripheral degradation, A can re-enter the brain. The best-known
factor mediating this influx through the BBB is receptor for advanced glycation end
products (RAGE, also known as AGER) (Zlokovic, 2004). RAGE is a member of the
immunoglobulin superfamily, which binds a wide variety of ligands (Yan et al., 2000). The
expression  of  RAGE is  regulated  by  the  expression  or  accumulation  of  its  ligands.  In  AD
brain and in mouse model of AD, accumulation of A species increases the expression of
RAGE in the affected cerebral vessels, neurons and microglia (Yan et al., 2000). RAGE binds
soluble A in the nanomolar range and it mediates transport of pathophysiologically
relevant concentrations of A from bloodstream to the brain via BBB. The deletion of the
RAGE gene has been shown to eliminate the transport of free circulating A to the brain
(Deane et al., 2003).
2.4.2.3 The role of APOE
As mentioned earlier (chapter 2.2.2), the genetic variation in APOE gene is the strongest
known risk factor in LOAD and the APOE isoforms have been shown to differentially affect
 deposition and clearance as well as other, A-independent functions such as synaptic
plasticity (Chen et al., 2010), lipid metabolism (Hamanaka et al., 2000), and
neuroinflammation (Keene et al., 2011) (Figure 9). -amyloid plaques have been shown to
be more abundant in APOE 4 carriers than in non-carriers (Polvikoski et al., 1995).
Furthermore, APOE 4 carriers have reduced CSF A42 levels and increased cerebral A
deposition in PiB-PET imaging in all age groups as compared to non-carriers (Morris et al.,
2010). APOE has been found to be co-deposited in -amyloid plaques in AD brain (Namba
et al., 1991) and the APOE4 isoform has been shown to bind A with lower affinity than
APOE3 (LaDu et al., 1994), suggesting that APOE4 might be less efficient in mediating the
clearance of A. Furthermore, APOE4 impedes the clearance of A through the BBB (Deane
et al., 2008) and is less efficient in enzyme-mediated A degradation as compared to
APOE3 (Jiang et al., 2008). However, the exact molecular mechanisms by which APOE
isoforms differentially regulate A aggregation and deposition are far from clear.
APOE is a lipoprotein composed of 299 amino acids with a molecular weight of 34 kDa
(Mahley and Rall, 2000). The three different alleles of APOE correspond to amino acid
variations at positions 112 and 158, where either cysteine or arginine is present: 2 (Cys112,
Cys158), 3 (Cys112, Arg158), and 4 (Arg112, Arg158). In the periphery, APOE is mainly
produced by the liver and macrophages and it participates in cholesterol metabolism. In the
CNS, APOE is the major apolipoprotein and it is produced primarily by astrocytes but also
by microglia (Xu et al., 2006). APOE transports cholesterol to neurons via APOE receptors,
which are members of the low-density lipoprotein receptor (LDLR) family, similarly to
LRP1 (Bu, 2009).
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Figure 9. Schematic presentation of apolipoprotein E (APOE) and amyloid- (A) metabolism in the brain.
The most important A clearance pathways are receptor-mediated uptake by neurons and glia, removal to
the interstitial fluid or to blood through the blood-brain-barrier (BBB), and proteolytic degradation by the
-degrading enzymes IDE and NEP. Impairment in A clearance can lead to the accumulation and
oligomerization of A in the brain parenchyma and finally to the formation of -amyloid plaques. A can
also accumulate in small blood vessels, leading to cerebral amyloid angiopathy (CAA). APOE is synthesized
by astrocytes and microglia. The ABCA1 transporter produced by astrocytes lipidates APOE to form
lipoprotein particles. Lipidated APOE binds soluble A and facilitates receptor-mediated uptake through
LRP1,  LDLR  and  HSPG.  APOE  disturbs  A clearance  through  the  BBB  and  facilitates  binding  and
internalization of soluble A in an isoform-dependent manner (APOE4 > APOE3 > APOE2). ABCA1, ATP-
binding cassette A1; HSPG, heparan sulphate proteoglycan; IDE, insulin-degrading enzyme; LDLR, low-
density lipoprotein receptor; LRP1, low-density lipoprotein receptor-related protein 1; LXR, liver X
receptor. (Reproduced by permission from Macmillan Publishers Ltd: NATURE REVIEWS NEUROLOGY, Liu,
C.-C. et al. Nat. Rev. Neurol. advance online publication 8 January 2013; doi:10.1038/nrneurol.2012.263,
copyright 2013)
APOE has been shown to affect brain A levels and the -amyloid plaque load in both
humans and transgenic mice in isoform-dependent manner (Castellano et al., 2011; Reiman
et al., 2009). This might be explained by the finding that APOE4 is less efficient in A
clearance than APOE3 in an AD mouse model expressing human APOE isoforms
(Castellano et al., 2011). Furthermore, in the same study, the effect of APOE genotype on
the cerebral A deposition using CSF A42 and PiB-PET biomarkers was studied among
cognitively normal individuals under the age of 70. The CSF A42 levels were significantly
lower among APOE
4/4 individuals as compared to the individuals having other APOE
genotypes and the mean concentrations of CSF A42 were found to be APOE allele-
dependent (4 < 3 < 2). Furthermore, PiB-PET results followed a strong APOE allele-
dependent pattern, with the highest frequency of PiB-positive individuals in the APOE
4/4 group (Castellano et al., 2011).
The levels of APOE might also affect A pathology. APOE knockout mice have more rapid
brain A clearance than control mice (DeMattos et al., 2004). In contrast, agonists increasing
APOE levels have also been shown to lead to the augmented clearance of A (Jiang et al.,
2008; Cramer et al., 2012). This discrepancy could be explained by the finding that free A
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is transported through the BBB faster than A bound to APOE and that APOE disrupts this
transport in an isoform-specific manner (E4 < E3 < E2)(Deane et al., 2008). While mice have
only one isoform of APOE, the existence of three different isoforms of APOE in humans
complicates this issue. In mice in which the native APOE has been replaced by human
APOE isoforms, the CSF and brain APOE levels are APOE genotype-dependent (4 < 3 <
2). This result indicates that lower levels of total APOE observed in APOE
 4 carriers
possibly contribute to the progression of the disease (Poirier, 2005). However, the effect of
APOE genotype on the CSF and brain APOE protein levels will require further
investigation.
The lower A binding affinity of APOE4 has been postulated to correlate with less efficient
 clearance (LaDu et al., 1994). Furthermore, in vitro studies with microglia have shown
that APOE3 is more efficient in promoting the enzyme-mediated A degradation than
APOE4 (Jiang et al., 2008). The lipidation status of APOE has also been postulated to affect
the A clearance. The ATP-binding cassette transporter A1 (ABCA1) lipidates APOE
leading to the formation of lipoprotein particles. In mice expressing human APOE4, but not
in mice expressing human APOE3, the lack of one copy of ABCA1 gene leads to impaired
 clearance, aggravated A deposition, and memory deficits (Fitz et al., 2012). Overall,
these results strongly suggest that APOE affects A clearance in an isoform-dependent
manner.
2.4.2.4 Liver X receptor 
Liver X receptors  and  (LXR) are ligand-activated transcription factors encoded by
genes called nuclear receptor subfamily 1, group H, member 3 and 2 (NR1H3 and NR1H2),
respectively. LXR is expressed particularly in the liver and macrophages, but also in the
brain, while LXR is ubiquitously expressed. Cholesterol-derived oxysterols are
endogenous ligands of these receptors (Lehmann et al., 1997) and the role of these receptors
is better understood in the periphery. These receptors sense excess cholesterol and trigger
adaptive mechanisms to protect cells from cholesterol overload. Activated LXR stimulates
cholesterol removal by ABCA1 and ABCG1 onto the cholesterol carriers, such as APOE,
which leads to biliary excretion of cholesterol (Kapur et al., 2008). LXR also may possess
anti-inflammatory effects by repressing inflammatory genes (Joseph et al., 2003). However,
the properties of these receptors in the brain have only recently been investigated.
Type II nuclear receptors, including LXRs and peroxisome proliferator-activated receptors
(PPARs), heterodimerize with retinoid X receptor (RXR) to form functional transcription
factors.  The  activation  of  LXRs  or  RXR  has  been  shown  to  increase  the  levels  of  both
ABCA1 and ApoE (Jiang et al., 2008; Cramer et al., 2012). LXRs have been shown to play
crucial roles in the CNS, since adult LXR knockout mice have motor neuron degeneration,
axonal dystrophy, astrogliosis, and lipid accumulation (Andersson et al., 2005). Mice
lacking both LXR and  display a wide variety of abnormalities in the brain, such as the
accumulation of lipid droplets, loss of neurons, astrocytic proliferation, closure of the
ventricles, and abnormalities in the vasculature (Wang et al., 2002). Importantly, genetic
loss  of  either  LXR or   in  an AD mouse model  increases  the  -amyloid burden without
affecting APP levels or processing (Zelcer et al., 2007). Furthermore, genetic deficiency of
LXRs reduced brain ABCA1 level ~40% in AD mice (Zelcer et al., 2007). This confirms the
proposal that the effects of LXRs in AD are mediated at least partly by ABCA1.
ABCA1 deficiency in mice, in turn, leads to ~80% decrease in APOE levels in brain tissue,
CSF and plasma (Wahrle et al., 2004). Moreover, crossing of ABCA1-deficient mice with
two different AD model mice leads to a phenotype with 70-80% reduced APOE levels and
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significantly increased A load with unaltered A production rate (Koldamova et al., 2005;
Wahrle et al., 2005). In contrast, six-fold overexpression of ABCA1 in the brain of AD model
mice has been shown to eliminate the formation of mature A plaques without alterations
in APP processing (Wahrle et al., 2008).
Synthetic agonists of both LXR and RXR have prominent effects on A clearance (Jiang et
al., 2008; Cramer et al., 2012). LXR agonists have been shown to stimulate the transcription
of LXR target genes, ABCA1 and APOE, in the brain leading to a reduction in both A40
and A42 levels, decrease in A plaque number and amelioration of behavioural deficits in
the AD mouse model (Jiang et al., 2008; Riddell et al., 2007). An LXR agonist has also been
shown to increase the A clearance ability of microglia through neprilysin and IDE, and
this effect is dependent on both ABCA1 and APOE (Jiang et al., 2008). Unfortunately, long-
term treatment with synthetic LXR agonists has induced hepatic steatosis, preventing
their proceeding into clinical trials.
The RXR agonist, bexarotene, has also been claimed to reduce soluble A levels and the
amyloid plaque burden as well as to be able to reverse cognitive deficits in two different
AD mouse models after short- and long-term administration of the drug (Cramer et al.,
2012). However, several other studies have failed to replicate in full these results (Fitz et al.,
2013; Price et al., 2013; Tesseur et al., 2013; Veeraraghavalu et al., 2013). Nevertheless,
studies with LXR and RXR agonists have provided a functional linkage between a major
genetic risk factor of AD and the clearance of A.
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3 Aims of the study
The goal of this thesis was to shed light on the pathogenesis of AD by investigating the
genetic and functional role of specific candidate genes in AD. Novel molecular knowledge
about factors involved in the pathogenesis of AD is needed to advance the identification
and the development of biomarkers and potential therapeutic interventions. This would
enable earlier diagnosis and development of better and more specific drugs for the
treatment of AD patients.
The specific aims were the follows:
1. To  study the  risk  effects  of  12  genes  known to  be  involved  in  A degradation and
clearance in AD (Study I)
2. To assess whether the genetic alteration in NR1H3, the gene encoding LXR, would
affect the expression of LXR or its downstream targets  APOE, ABCA1, and ABCG1
as well as modifying the levels of soluble A42 and -secretase activity in the inferior
temporal cortex of AD patients at different stages of the disease (Study II)
3. To elucidate the functional and/or genetic role of GGA3 and p-eIF2, central factors
regulating BACE1, using a post-mortem AD brain sample set and genetic AD case-
control and family-based cohorts (Study III)
4. To investigate the effects of the AD-associated protein ubiquilin-1 on BACE1 using
the human post-mortem sample set, in vitro models and lentiviral gene delivery in
vivo in an AD mouse model (Study IV)
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4 Subjects, Materials and Methods
4.1 SUBJECTS
4.1.1 AD case-control cohort (Studies I and III)
The AD case–control cohort was used in studies I and III for genetic association
assessments (Table 6). All AD patients fulfilled the NINCDS-ADRDA criteria for probable
AD (McKhann et al., 1984). Control subjects had no signs of dementia based on interview
and neuropsychological testing (Hanninen et al., 2002). The subjects whose onset age of the
disease was 65 years did not show any conclusive evidence of autosomal dominant
transmission and there were no APP, PSEN1 or PSEN2 mutations. All subjects originated
from Eastern Finland and were examined in the Department of Neurology, Kuopio
University Hospital.
Table 6. Demographics of Finnish AD case-control cohort (studies I and III)
AD cases Controls
Study I 642 682
(women, % in status) (67.6) (60.3)
Study III 673 686
(women, % in status) (67.5) (60.3)
mean age at onset 71±7 69±6*
age range 43 to 89 37 to 87
* Mean age at neuropsychological examination
4.1.2 Family based sample set (Study III)
Four AD family sample sets consisting primarily of siblings were used in study III (Table 7).
These cohorts were from the National Institute of Mental Health AD Genetics Initiative
(NIMH)(Blacker et al., 1997; Blacker et al., 2003), the National Cell Repository for
Alzheimer’s Disease (NCRAD), the National Institute on Aging Genetics Initiative for Late
Onset Alzheimer’s Disease (NIA-LOAD) (details of the NCRAD and NIA-LOAD cohorts
are available at the NCRAD website, http://www.ncrad.org), and the Consortium on
Alzheimer’s Genetics (CAG) (Bertram et al., 2005).
Table 7. Number of subjects in four family-based sample sets in study III
Sample set Affected (N) Unaffected (N)
NIMH 994 405
NCRAD 830 309
NIA-LOAD 757 290
CAG 195 255
NIMH, National Institute of Mental Health AD Genetics Initiative; NCRAD, National Cell Repository for
Alzheimer’s Disease; NIA-LOAD, National Institute on Aging Genetics Initiative for Late Onset Alzheimer’s
Disease; CAG, Consortium on Alzheimer’s Genetics
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4.1.3 Neuropathological sample set (Studies II, III and IV)
The human post-mortem brain samples were obtained from Kuopio University Hospital.
The first set in study III included temporal cortex samples of three AD subjects (2 females
and 1 male; mean age 78.0 ± SD 3.8 years) and four age-matched controls (2 females and 2
males; mean age 88.0 ± SD 6.9 years). The samples were from the set used in a previous
study (Iivonen et al., 2002), in which the CERAD criteria were used to determine the
diagnosis of AD (Mirra et al., 1991).
The second sample set in study III, and sample sets in studies II and IV included inferior
temporal lobe samples from elderly individuals investigated within memory clinic research
projects and later autopsied and evaluated for AD pathology (Table 8). The sets were
classified into three groups; mild, moderate and severe according to Braak staging (0-
2=mild, 3-4=moderate, 5-6=severe) (Braak et al., 2006a). The Ethics Committee of the Kuopio
University Hospital and University of Eastern Finland approved the study.
Table 8. Demographics and pathology of the subjects in neuropathological sample set
N,
total
Severitya N Gender:
males/
females
Age at
death,
mean
(years)
PMDb,
mean
(hours)
Brain weight,
mean (g)
Study II 87
MILD 46 17/29 80.7 ± 9.7 17.7 ± 21.6 1215 ± 180
MODERATE 14 2/12 83.5 ± 7.0 15.9 ± 15.5 1101 ± 150
SEVERE 27 2/25 81.6 ± 7.4 6.5 ± 4.5 1031 ± 171
Study III 24
MILD 10 4/6 83.2 ± 4.4 17.1 ± 11.7 1321 ± 182
MODERATE 7 1/6 81.0 ± 10.5 13.7 ± 16.8 1091 ± 138
SEVERE 7 0/7 85.0 ± 4.4 9.3 ± 7.0 1009 ± 151
Study IV 60
MILD 28 14/14 79.2 ± 10.9 18.0 ± 19.6 1250 ± 183
MODERATE 13 2/11 82.9 ± 6.8 15.8 ± 16.1 1104 ± 156
SEVERE 19 2/17 81.3 ± 7.0 7.1 ± 5.0 1040 ± 183
a) Classification to mild, moderate and severe groups according to Braak staging; 0-2=mild, 3-
4=moderate, 5-6=severe
b) Post-mortem delay
4.2 GENOTYPING (STUDIES I, II AND III)
Study I
Lymphocyte-derived DNA samples from Finnish AD-control cohort were randomly placed
on 384-well plates and genotyped using Sequenom iPLEX platform (Sequenom®,
Hamburg, Germany). A total of 12 genes which are known to encode enzymes or proteins
involved in A degradation or clearance were selected for genotyping (Table 9). SNPs were
selected from these 12 genes on the basis of the CEU genotype information retrieved from
the HapMap database (www.hapmap.org; HapMap Data Rel 27 Phase II+III) so that the
selected SNPs captured the genetic information within the studied gene regions.
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Table 9. Summary of genes and their polymorphisms among Finnish AD-control cohort analyzed
in study I
Gene Chromosome Polymorphism Allele
variationa
AD cases (N) Controls
MMEL1 1 rs12117343 C/T 616 663
ECE1 1 rs2038090 A/C 619 659
rs3026883 G/T 585 594
rs2236847 C/T 557 588
rs212548 A/G 620 656
ECE2 3 rs902415 A/G 563 588
rs9824 G/A 615 657
rs3914188 G/C 614 662
AGER 6 rs1800684 A/T 611 655
PLG 6 rs4252065 C/T 555 588
rs3757019 G/A 621 661
rs783182 T/C 561 589
PLAT 8 rs2020922 T/A 566 593
rs879293 G/A 607 642
rs7837156 T/G 556 588
NR1H3 11 rs12221497 G/A 565 593
rs2279238 G/A 560 589
rs7120118 T/C 581 592
MMP3 11 rs639752 T/G 616 648
rs678815 G/C 549 580
LRP1 12 rs4759275 G/A 603 654
rs1799986 C/T 587 600
rs1800139 T/C 612 657
TTR 18 rs723744 C/A 602 653
rs1080093 C/G 585 600
rs3794884 A/C 562 590
NR1H2 19 rs2695121 C/T 616 653
rs1405655 T/C 609 661
rs4802703 C/A 609 657
MMP9 20 rs17576 A/G 562 592
rs13925 G/A 619 657
a) Major/minor allele based on information from HapMap and NCBI SNP -databases
Study II
DNA samples extracted from 87 post-mortem brain tissue samples were genotyped for SNP
rs7180118 in the NR1H3 gene. PCR was conducted around the rs7180118 site by using the
following primers: 5’-GCTCTCCCCTCCTTCAGAAT-3’ and 5’-
CACGGAATGAACACCTCAAA-3’.
Study III
DNA samples from the Finnish AD-control cohort were genotyped using Sequenom iPLEX
platform as in study I. Six tag SNPs from the GGA3 gene (Table 10) were selected using the
CEU genotype information retrieved from the HapMap database (HapMap Genome
Browser release #28, Phase II + III, http://hapmap.ncbi.nlm.nih.gov/) and Haploview4.2
program so that SNPs captured the entire genetic information from three identified
haplotype blocks in the gene region.
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Table 10. Summary of SNPs and their allelic variation among Finnish
AD case –control cohort analyzed in study III
SNP Allele variationa AD cases (N) Controls (N)
rs8073890 C/T 566 587
rs1471454 C/A 652 666
rs2242230 G/A 619 665
rs11077781 A/C 609 649
rs9988 T/C 654 667
rs2291031 C/T 568 589
a) Major/minor allele based on information from HapMap and NCBI SNP -databases
Five SNPs from the GGA3 gene region (Table 11) were genotyped in NIMH, NCRAD,
NIA-LOAD, and CAG cohorts. These tag SNPs in the GGA3 region were selected
independently and they are located in three haplotype blocks identified using the
Haploview 4.2 program. The genotyping of the SNPs was implemented using the
fluorescence polarization–detected single base extension method (Bertram et al., 2005) on a
Criterion Analyst AD high-throughput fluorescence detection system (Molecular Devices).
Table 11. Summary of SNPs and their allelic variation among family-based
NIMH, NCRAD, NIA and CAG sample cohorts analyzed in study III
SNP Allele variationa
rs8075276 A/G
rs17568408 C/T
rs1471454 A/C
rs78740665 C/G
rs9988 C/T
a) Major/minor allele based on information from HapMap and NCBI SNP -databases
DNA samples from the 24 human postmortem brain tissue samples were extracted and
genotyped for SNP rs2242230 in GGA3 gene using cycle sequencing. PCR was conducted
by using the following primers: 5’-TTTCTGTCTCCTTGCTACTGACTG-3’ and 5’-
CACTAAGCCTGGGGCTACCT-3’. After the purification of PCR products, they were
sequenced using BigDye™ Terminator sequencing kit (Applied Biosystems) and ABI
PRISM® 3100 Genetic Analyzer (Applied Biosystems)
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4.3 CSF BIOMARKER ANALYSIS (STUDIES I, II AND III)
The CSF levels of A42, total tau (tot-tau) and phosphorylated tau (p-tau, phosphorylated
at Thr181) (Table 12) of the AD patients were measured by using commercially available
enzyme-linked immunosorbent assays (INNOTEST® ß-AMYLOID(1-42), tot-tau,
INNOTEST hTAU Ag, p-tau, INNOTEST PHOSPHO-TAU(181P), Innogenetics, Ghent,
Belgium).
Table 12. Number of AD patients with CSF biomarker samples
42 (N) tot-tau (N) p-tau (N)
Study I 124 59 54
Study II 28 27 27
Study III 222 159 151
4.4 DNA EXTRACTION FROM THE BRAIN TISSUE SAMPLES (STUDIES II,
III AND IV)
Frozen inferior temporal lobe samples were homogenized in TRI-reagent (10 ml TRI-
reagent / 1 g brain tissue) and DNA was isolated from 1 ml of Tri-reagent homogenate. 0.5
ml of Back extraction buffer (4 M guanidine thiocyanate; 50 mM sodium citrate; 1 M Tris,
pH 8.0) was added to the homogenate and the samples were mixed for 15 sec and
incubated for 10 min at room temperature. The organic and inorganic phases were
separated by centrifugation at 12000 x g for 15 min at +4°C. The aqueous phase containing
DNA was transferred to a clean tube and the organic phase was saved for the subsequent
protein isolation. DNA was precipitated by adding 0.5 ml of isopropanol. Samples were
mixed and incubated for 30 min at -20°C. DNA was collected by centrifugation at 12000 x g
for 25 min at +4C° and the supernatant was removed. DNA pellets were washed twice with
1.0 ml of 75 % ethanol. Air-dried DNA was dissolved in 50 μl of Tris-EDTA buffer (10 mM
Tris; 0.1 mM EDTA, pH 8.0).
4.5 EXTRACTION OF RNA FROM THE BRAIN TISSUE SAMPLES (STUDIES
II, III AND IV)
The first set including 24 brain samples used in study III was homogenized in TRI-reagent.
Homogenates were treated twice with Tissuelyser (Qiagen) for 2 min at +4°C. One fifth of
the volume of TRI-reagent of chloroform was added to samples and the samples were
mixed by shaking. Mixtures were incubated at room temperature for 5 min and the phase
separation was performed by centrifugation at 12000 x g for 20 min at +4°C. The aqueous
phase containing RNA was transferred to clean tubes and RNA was precipitated with
isopropanol by mixing and incubating at room temperature for 30 min. Samples were
centrifuged at 12000 x g for 25 min at +4°C and the pellets were washed twice with 75%
ethanol. RNA pellets were air-dried and dissolved in RNAse-free H2O. RNA from the
second set including 63 brain samples was extracted using Qiagen RNeasy Lipid Tissue
Mini Kit (Qiagen). The first and the second set together formed the sample set for study II,
containing a total of 87 post-mortem brain samples. Subsequently, 60 samples with the best
RNA quality were used in study IV. The quality of RNA samples was determined using
2100 Bioanalyser (Agilent). RNA samples were categorized into three subgroups according
to the RNA integrity number (RIN) values; <4, <6 or <8. The distribution of RNA samples
based on the RIN values among the whole set with 87 samples was 41.0% (RIN<4), 28.2%
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(RIN<6) and 30.8% (RIN<8). The distribution of RIN values in the TRI-reagent extracted
samples was 13.0% (RIN<4), 47.8% (RIN<6) and 39.2% (RIN<8), while in the RNeasy Lipid
Tissue Mini Kit extracted samples it was 50.0% (RIN<4), 24.1% (RIN<6) and 25.9% (RIN<8).
The post-mortem delay did not correlate with the RIN values (Pearson’s correlation, r=-
0.09, p=0.40) and the RNA quality did not correlate with expression levels of any gene
studied.
4.6 ANALYSIS OF RNA (STUDIES II, III AND IV)
In studies II and III, cDNAs were synthethized from equal amounts of total RNA using
Dynamo qPCR kit (Finnzymes). Primers and probes for qPCR were designed using Roche
Universal Probe Library (www.roche-applied-science.com/sis/rtpcr/upl/ezhome.html)
(Table 13). KAPA PROBE FAST qPCR kit was used for the amplification of cDNA samples
by real-time quantitative PCR (7900HT, Applied Biosystems). The comparative Ct
method was used to analyze the GAPDH-normalized GGA3, NR1H3, ABCA1, ABCG1 and
APOE mRNA levels.
Table 13. Summary of primers and probes used in qPCR in studies II and III
Gene F-primer (in 5' - 3' order) R-primer (in 5' - 3' order) Probe
Study II NR1H3 GTTATAACCGGGAAGACTTTGC AAACTCGGCATCATTGAGTTG 80
ABCA1 GGCCTACCAAGGGAGAAACT TGTCATCACATGTCACATCCA 84
ABCG1 TCAGGGACCTTTCCTATTCG TTCCTTTCAGGAGGGTCTTGT 22
APOE GGACGAGGTGAAGGAGCA CTGCAGGCGTATCTGCTG 64
GAPDH GCATCCTGGGCTACACTGA CCAGCGTCAAAGGTGGAG 82
-actin CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG 11
Study III GGA3 CAGTCCCCACAGGAATGG CCTCCCACAGTTCTTCATGC 67
GAPDH CTCTGCTCCTCCTGTTCGAC ACGACCAAATCCGTTGACTC 60
-actin CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG 64
In study IV, expression levels of UBQLN1 was investigated from 60 RNA samples extracted
from the inferior temporal cortex (the neuropathological sample cohort) by assessing
expression levels using probes targeting five exons (exons 2; 4; 6; 9 and 11). This
measurement was implemented using Agilent One-Color Microarray-Based Exon Analysis.
One hundred ng of total RNA was amplified and labelled using Low Input Quick Amp WT
Labeling –kit (Agilent, product number 5190-2943). Samples were processed with RNA
Spike in –kit (Agilent, product number 5188-5282). Concentrations of starting material and
amplified/labelled cRNA were measured by Nano-Drop ND-2000. Quality of RNA and
cRNA was analyzed using Agilent 2100 bioanalyzer and RNA 6000 Nano –kit (Agilent,
product number 5067-1511). Six hundred ng of Cy3-labeled samples were hybridized to
Agilent 8x60K custom exon chip (Design ID 044312) overnight at +65C using Gene
Expression Hybridization kit (Agilent, Product number 5188-5242). Subsequently, samples
were washed using Gene Expression Wash Pack (Agilent, Product number 5188-5327) and
the chips were scanned with Agilent Technologies Scanner, model G2565CA. Numeric data
was produced by Agilent Feature Extraction software, version 10.7.3.
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4.7 PROTEIN EXTRACTION FROM THE BRAIN TISSUE SAMPLES
(STUDIES II, III AND IV)
Proteins from dissected temporal cortex tissue samples of three AD and four control brains
used in study III were extracted by homogenizing the samples in T-PER® tissue protein
extraction reagent (Thermo Scientific) containing EDTA-free protease inhibitor cocktail
(Thermo Scientific) and Halt™ phosphatase inhibitor cocktail (Thermo Scientific). Samples
were centrifuged at 10000 x g for 10 min and the supernatants containing total proteins
were used for Western blot analysis.
Protein extraction from the neuropathological sample cohort used in studies II, III and IV
was conducted from the phenol-ethanol supernatant obtained after the extraction of DNA
from the inferior temporal lobe of a total of 87 subjects. Three volumes of acetone were
added to the organic phase (including the interphase) from DNA extraction. Samples were
mixed and incubated at room temperature for 10 min and centrifuged for 10 min at 10000 x
g at +4°C. The supernatants were removed and the pellets were suspended in 0.5 ml of 0.3
M guanidine hydrochloride in 95% ethanol + 2.5 % glycerol (1:1). 0.5 ml of the guanidine
hydrochloride/ethanol/glycerol wash solution was added to the samples which were then
incubated for 20 min at room temperature. The samples were centrifuged at 10000 x g for 10
min and the supernatants were discarded. The pellets were washed twice in 1 ml of
guanidine/ethanol/glycerol wash solution. The final wash was performed in 1 ml of ethanol
containing 2.5 % glycerol (vol/vol) by incubating for 10 min at room temperature. The
samples were centrifuged at 8000 x g for 5 min. The pellets were air-dried for 10 min at
room temperature and dissolved in UREA-CHAPS (9.5 M Urea and 2% CHAPS [3-[(3-
cholamidopropyl)-dimethylammonio]propanesulfonate], pH 9.1) with shaking for 15 min
at room temperature.
4.8 WESTERN BLOT ANALYSIS (STUDIES II, III AND IV)
Protein concentrations were determined using BCA protein assay (Pierce). The proteins (15-
50 μg/lane) were separated on 4-12% Bis-Tris-polyacrylamide gel electrophoresis (PAGE;
Invitrogen) under reducing conditions and subsequently blotted onto polyvinylidene
difluoride membranes (Amersham Hybond-P, GE Healthcare). Appropriate primary
antibodies were used for immunoblotting (Table 14). After incubation with the suitable
horseradish peroxidase (HRP) -conjugated secondary antibodies, the protein bands were
detected using enhanced chemiluminescence (ECL, ECL+ or ECL Advance) substrate
(Amersham, GE Healthcare) and ImageQuant RT ECL camera (GE Healthcare). The band
intensities were quantified by Quantity One software (Bio-Rad).
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Table 14. Primary antibodies used in Western blotting, immunofluorescence and
immunohistochemical stainings.
Antibody Supplier Cat no Origin  Clonality
dilutions
WBa IFb IHCc
APP (A8717) Sigma Aldrich A8717 Rabbit  Poly 1:2000
ARF6 (3A-1) Santa Cruz
Biotechnology
sc-7971 Mouse Mono 1:1000
 (6E10) BioSite SIG-39320 Mouse Mono 1:1000
BACE1 (61-3E7) Santa Cruz
Biotechnology
sc-33711 Mouse Mono 1:100 1:50
BACE1 (D10E5) Cell Signaling 5606 Rabbit Mono 1:1000 1:250 1:1000
BACE1 (PA1-757) Thermo Scientific PA1-757 Rabbit  Poly 1:1000 1:200
CD45 Serotec 1388 Mouse Mono 1:100
EEA1 BD Transduction
Laboratories
610456 Mouse Mono 1:200
eIF2 Cell Signaling 9722 Rabbit Poly 1:1000
GAPDH (6C5) Abcam ab8245 Mouse Mono 1:15000
GFAP Sigma G3893 Mouse Mono 1:1000
GFP Roche 118144600
01
Mouse Mono 1:1000
GGA1 Abcam ab38454 Rabbit Poly 1:100
GGA3 BD Transduction
Laboratories
612310 Mouse Mono 1:2500
Myc (clone 4A6) Millipore 05-724 Mouse Mono 1:1000
pan-A Invitrogen 44-136 Rabbit Poly 1:300
phospho-eIF2
(Ser 51)
Cell Signaling 3597 Rabbit Mono 1:1000
phospho-Tau
(AT8)
Pierce
Biotechnology
MN1020 Mouse Mono 1:1000
Rab 7 (B-3) Sant Cruz sc-376362 Mouse Mono 1:50
Seladin-1/DHCR24 Cell Signaling 2033 Rabbit Mono 1:1000
Tau Abcam ab47579 Rabbit Poly 1:1000
TfR Zymed 13-6800 Mouse Mono 1:1000 1:200
ubiquilin-1 Invitrogen 35-4400 Mouse Mono 1:500
ubiquilin-1
(U7258)
Sigma Aldrich U7258 Rabbit Poly 1:1000
ubiquitin-48 Millipore 05-1307 Rabbit Mono 1:1000
ubiquitin-63 Millipore 05-1308 Rabbit Mono 1:1000
-actin Abcam ab8226 Mouse Mono 1:1000
a) Western blot; b) Immunofluorescence; c) Immunohistochemistry
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4.9 -SECRETASE ACTIVITY ASSAY FROM THE TISSUE SAMPLES
(STUDIES II, III AND IV)
-secretase activities were measured from human inferior temporal lobe and mouse
hippocampal tissue samples. Frozen human temporal lobe samples were mechanically
homogenized in an ice bath in 400 l of buffer B (20 mM Hepes pH 7.5, 150 mM KCl, 2 mM
EGTA) containing 1:100 EDTA-free protease inhibitor cocktail (Thermo Scientific) and
Halt™ phosphatase inhibitor cocktail (Thermo Scientific). After one-hour centrifugation in
100000 × g (50.4 Ti rotor; Beckman) at +4 °C, the supernatant was collected and stored at -
70°C for soluble A x-42 measurements. The remaining pellet was washed with buffer B
and the samples were centrifuged at 100000 × g for 30 min at +4 °C. The supernatant was
removed and the pellet was solubilized in buffer B containing 1% CHAPSO (3-[(3-
Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate; Cat #220202,
Calbiochem) by rotation at +4 °C for 1 hour and centrifuged at 100000 × g for 1 h to collect
the supernatant (=membrane fraction) for the -secretase activity assay. Mouse
hippocampal tissue samples, in turn, were mechanically homogenized in an ice bath in
1 x PBS. The -Secretase Activity Assay Kit (Cat #K360-100, BioVision, CA, USA) was used
to measure -secretase activity from tissue samples according to the manufacturer's
instructions as follows. Equal amounts (1,5 g) of  protein fractions from both human and
mouse brain samples  were incubated at +37°C for one hour with the -secretase-specific
fluorogenic substrate peptide conjugated to fluorescent reporter molecules EDANS and
DABCYL.  In order to inhibit -secretase activity (specificity control), 150 mM -secretase
inhibitor GL189 (H-VENstatineVAEF-NH2; Product #565780-500MG, Calbiochem) was
added to randomly selected samples. Subsequently, the emitted light (510 nm) was
detected on a fluorescence microplate reader after EDANS excitation at 355 nm. Readings
obtained from substrate alone (without secretase) were subtracted before calculating the
fold change in -secretase activity. An average 50% reduction in -secretase activity was
observed in samples treated with the -secretase inhibitor GL189.
4.10 A MEASUREMENTS FROM THE TISSUE SAMPLES (STUDIES II, III
AND IV)
Soluble A x-42 levels from the human inferior temporal lobe samples in studies II and III
were measured in the supernatants collected from the -secretase activity assay (see sample
preparation for the -secretase activity assay). Mouse hippocampal tissue samples in study
IV were mechanically homogenized in an ice bath in 1 x PBS containing EDTA-free
protease inhibitor cocktail (Thermo Scientific) and Halt™ phosphatase inhibitor cocktail
(Thermo Scientific) with 50 μl of homogenate being centrifuged at 100000 x g for 2 h at
+4 °C. Supernatants containing soluble fraction of A were moved to clean tubes. Pellets
containing the insoluble fraction were solubilized in 200 μl 5M Guanidine HCl by vortexing
for 3 h at room temperature. The samples were centrifuged at 10000 x g for 10 s and protein
quantification of supernatants was performed using the BCA protein assay (Pierce). A x-
40 and A x-42 levels were measured using Human/Rat  Amyloid 40 (Cat no 294-64701)
and Human/Rat  Amyloid 42 (Cat no 292-64501) ELISA Kits (Wako). After a 30-minute
incubation at room temperature, the reaction was terminated and the absorbance was
measured at 450 nm using an ELISA microplate reader (BioRad). A concentrations were
normalized to total protein concentrations in each sample.
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4.11 CELL CULTURE EXPERIMENTS (STUDY IV)
4.11.1 Stable cell lines
Human neuroglioma H4 cells stably overexpressing APP751 isoform (H4 APP751), or
UBQLN1 transcript variant TV1 (H4 TV1-13,(Lu et al., 2009)) and human neuroblastoma
SH-SY5Y cells stably overexpressing APP751 isoform (SH-SY5Y-APP751) were cultured in a
humidified cell culture incubator in 5% CO2 atmosphere in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin (DMEM-C) and supplemented with 200 μg/ml geneticin.
The cells were plated onto cell culture dishes (Nunc).
4.11.2 Plasmid constructs and transfections
Plasmid encoding ubiquilin-1 TV1 (full-length, containing all 11 exons) in HIV vector,
5’3’UTR-BACE1 (human BACE1 containing endogenous 5’- and 3’- UTRs) in pEAK8 vector,
5’-UTR-BACE1 (human BACE1 containing endogenous 5’UTR) in pEAK8 vector, BACE1-
Myc (human BACE1 with CMV promoter region and myc-tag in C-terminus) in pcDNA3.1
vector and pEGFP-F (Clontech) were used for transfections. The 5’3’UTR-BACE1 and 5’-
UTR-BACE1 constructs were generously provided by Prof. Stefan Lichtenthaler (DZNE -
German Center for Neurodegenerative Diseases, Munich, Germany). pcDNA3.1 plasmid
was used as a control. The cells were transfected with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. The medium was changed 4 hours later and
the cells were harvested 24 hours after the transfection.
4.11.5 Protein extraction (Study IV)
The total proteins of in vitro -experiments were extracted by scraping the cells in an
appropriate volume of tissue protein extraction buffer (TPER, Pierce) containing EDTA-free
protease inhibitor cocktail (Thermo Scientific) and HALT™ phosphatase inhibitor cocktail
(Thermo Scientific). The protein lysates were centrifuged at 10000 x g for 10 minutes at
+4 °C and protein concentrations were measured from the supernatant using the BCA
protein assay kit (Pierce).
4.12 CYCLOHEXIMIDE ASSAY (STUDY IV)
The cycloheximide time course experiment was conducted using H4 TV1-13 cells
transfected with 5’3’UTR-BACE1 and control plasmids to determine the rate of protein
degradation. Cycloheximide is a compound which inhibits protein synthesis in eukaryotic
cells and this allows the temporal evaluation of the degradation of existing proteins.
Twentyfour hours after transfection, the cells were treated with 30 g/ml of cycloheximide
for 0, 6, and 12 h and subsequently the cells were washed with 1 x PBS and lysed in tissue
protein extraction buffer (TPER, Pierce) containing EDTA-free protease inhibitor cocktail
(Thermo Scientific) and HALT™ phosphatase inhibitor cocktail (Thermo Scientific). Equal
amounts of total protein were used in Western blot with BACE1- (PA1-757) and GAPDH-
specific antibodies. The half-life of BACE1 was calculated by plotting the BACE1 intensity
values (Normalized to BACE1 0-h value) with respect to different treatment times.
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4.13 IMMUNOPRECIPITATION (STUDY IV)
Immunoprecipitation was performed to study the ubiquitination status of BACE1 SH-
SY5Y-APP751 cells and APP in mouse hippocampal tissue samples. SH-SY5Y-APP751 cells
transfected with UBQLN1 TV1-HIV and 5’3’UTR-BACE1 plasmids were harvested in RIPA-
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA and 0.5% Igepal) containing
Complete Mini EDTA-free protease inhibitor (Roche). The samples were centrifuged at
11000 x g for 10 min at +4 °C. Protein concentrations of supernatants were measured using
the BCA protein assay kit (Pierce) with 20μg of protein from each sample being added to
RIPA buffer to a final volume of 500 μl. Alternatively, 20 μg of protein from UBQLN1 TV1
lentivirus-injected mouse hippocampal extracts in PBS was added to RIPA buffer to a final
volume of 500 μl. Protein A/G beads (Pierce) were added to the proteins and incubated for
1 hour at +4°C. This preclearing phase is performed to reduce non-specific protein binding
in the actual immunoprecipitation reactions. The samples were centrifuged at 8000 x g for 1
minute. The supernatant was mixed with 2.5 μl anti-BACE1 (PA1-757)(SH-SY5Y-APP751
cells) or anti-APP (A8717)(hippocampal samples) antibody and rotated for 1 hour at +4°C.
Fresh protein A/G beads were added and the mixtures were rotated at +4°C overnight to
allow the formation of the bead-antibody-target protein -complex. The samples were
centrifuged at 8000 x g for 1 minute to pellet the complexes. Supernatant was removed and
immunoprecipitated complexes were washed 4 times with RIPA buffer and the precipitated
proteins were detached from the beads by heating at 55°C for 10 minutes in 30 μl 1x LDS
loading buffer (Novex) containing 5% -mercaptoethanol. The samples were centrifuged at
13000 x g for 15 minutes and the supernatants were analysed by Western blotting. Sample
without antibody (beads only) was used as a negative control. A sample with an antibody
(anti-rabbit secondary Ab, Ge Healthcare) known not to interact with BACE1/APP was
used as an additional control to check the specificity of the assay.
4.14 IMMUNOFLUORESCENCE STAININGS AND MICROSCOPY (STUDY
IV)
SH-SY5Y-APP751 cells used for immunofluorescence imaging were plated on sterile
coverslips coated with 100μg/ml poly-D-lysine (PDL, Sigma) and transfected with 5’3’UTR-
BACE1 and myc-TV1 plasmids while cells transfected with 5’3’UTR-BACE1 and pcDNA
served as a control. Twentyfour hours after transfection, the cells were fixed using 4%
paraformaldehyde for 15 min. The fixed cells were permeabilized by incubating 10 min in
PBS (DPBS, Lonza) containing 0.1% Triton-X (Sigma). Unspecific antibody binding was
blocked by incubating the cells for 30 min in 1.5% goat IgG in PBS. Following primary
antibodies were used and incubated with the cells for 1.5 h: BACE1 D10E5; Myc; Rab7; TfR
and EEA1 (details in table 14). This was followed by 1-h incubation with secondary Alexa
Fluor 488 goat anti-rabbit (1:500, Molecular Probes) and Alexa Fluor 594 goat anti-mouse
(1:500, Molecular Probes) antibodies. The nuclei were stained with DAPI (1:5000) for 5 min.
The images were taken with Zeiss Axio Imager using ApoTome.2 at 63 x magnification.
Colocalization of BACE1 and the subcellular markers was quantified using Zeiss ZEN
Module Colocalization analysis hardware.
4.15 AD MOUSE MODEL EXPERIMENTS (STUDY IV)
4.15.1 Animals
The animals were male APPswe/PS1dE9 (APdE9) mice (Jankowsky et al., 2004) (n=24). The
APdE9 founder mice were obtained from Johns Hopkins University, Baltimore, MD, USA
(D. Borchelt and J. Jankowsky, Dept. Pathology) and the colony was established at the
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University of Eastern Finland (Kuopio, Finland). This mouse line was originally maintained
in a hybrid C3HeJ × C57BL6/J F1 background, but the mice used in the present study were
derived from backcrossing to C57BL6/J for 15 generations. The housing conditions
(National Animal Center, Kuopio, Finland) were controlled (temperature +22°C, light from
07:00 to 19:00; humidity 50–60%), and fresh food and water were available ad libitum. The
experiments were conducted according to the Council of Europe (Directive 86/609) and
Finnish guidelines, and approved by the Animal Experiment Board of Finland (permit:
ESAVI/4677/04.10.03/2011). All experiments were designed and conducted in a manner
minimizing the use (e.g. only the minimal number of animals per group) and suffering of
animals.
4.15.2 Lentivirus injections
Genes encoding human ubiquilin-1-TV1 and GFP were cloned in lentivirus transfer (HIV)
plasmid using PCR-cloning method. The constructs were verified by sequencing. Ubiquilin-
TV1 (LV-TV1) and GFP (LV-GFP) expressing lentiviruses were prepared in triple flasks by
the calcium phosphate transfection method in 293T cells as described previously (Follenzi
and Naldini, 2002) and concentrated by ultracentrifugation. At the age of 5 months,
APP/PS1 mice were anesthetized with halothane and placed in a stereotactic frame (model
900; David Kopf). Before injections, lentiviral vectors were diluted in sterile PBS (pH 7.4) to
achieve a titer of 1.28 × 109. Viral preparations (LV-TV1, n=8; LV-GFP, n=8; and SHAM, n=8)
in 2-μl volume were injected bilaterally into the dentate gyrus of the hippocampus by using
the following coordinates: ±3.2 mm medial/lateral, 2.7 mm anterior, 2.7 mm ventral from
the bregma. The preparation was injected with a speed of 0.2 μl/min over a period of 10
min by using a Hamilton 10-μl syringe and a 28 G needle. Before waking, mice received
5mg/kg of carprofene s.c. (Rimadyl 50 mg/ml) and were allowed to recover in a heated
chamber. Animals were sacrificed at the age of 9.5 months. The right hemisphere was taken
for immunohistochemical analysis and the left hemisphere was dissected into hippocampal
and cortical samples prior to biochemical analysis.
4.15.3 Immunohistochemistry.
In the histological analysis, mice were deeply anesthetized and perfused transcardially with
50 ml heparinized ice-cold 0.9% saline. After dissection, the right hemisphere was fixed
with 4% paraformaldehyde for 4 h. The right hemisphere was left overnight at +4C in 30%
sucrose solution and finally stored in a cryoprotectant at –20 °C before sectioning on a
freezing microtome into 35 μm thick coronal sections with an interval of 200 μm. The
sections were pretreated for 30 min with hot (80 °C) 0.05 M sodium citrate solution (pH 6.0).
Brain sections from GFP injected mice were used as controls. Activated and proliferating
microglia were assessed after immunostaining with CD45 (1:100; Serotec). Human A was
detected with pan-A antibody (1:300; BioSource). Following incubation for 18 h on a
shaker table at room temperature (20 °C) in the dark, the sections were rinsed three times in
TBS-T and transferred to a solution containing the secondary antibody (goat anti-mouse-
biotin, Vector Laboratories, USA, 1:500). After 2 h, the sections were rinsed three times with
TBS-T and transferred to a solution containing mouse StreptAvidin (GE Healthcare, 1:1000).
After rinsing in TBS-T, the sections were incubated for approximately 3 min in Ni-enhanced
DAB solution. The sections were photographed using an Olympus BX40 microscope with
DP50 camera attached and images were treated and analyzed using Photoshop CS3
program. The images were transformed to grayscale and their brightness and contrast was
changed using the shadow-highlight command. The area of interest was selected using the
lasso-tool and amyloid plaques were measured using the color range command by using
threshold. The final value was obtained by dividing the amyloid plaque area by the total
hippocampal area. To specifically assess the influence of ubiquilin-1 on plaque-associated
BACE1, five equally spaced coronal sections through the hippocampus were stained with
45
anti-BACE1 antibody. The robust immunopositivity in CA3 neurons was excluded by
excising the CA3 pyramidal cell layer from all images before the analysis. The total BACE1
immunopositive area was then calculated with automated software as well as the total area
of the hippocampal cross-section (with CA3 excluded). The number of individual clusters
of immunopositive pixels (blobs) was counted automatically. Then the total BACE1-
positive area in each section was divided by the number of BACE1-positive blobs to obtain
the mean blob size in each section. The values of five individual sections were finally
averaged to obtain a grand mean BACE1-positive area as % of grand mean hippocampal
cross-section area. Similarly a grand mean BACE1 blob size was calculated and expressed
as % of grand mean size of BACE1 positivity (= plaque).
4.16 STATISTICAL ANALYSIS
SPSS 17.0 software was utilized for statistical testing. In the genetic studies (studies I and II)
single locus allele and genotype frequencies using Pearson 2 test and Kaplan-Meier
survival analyses were performed to define disease association and age of onset effects with
the studied SNPs among Finnish AD case-control cohort. Univariate logistic regression
analysis was applied to assess the risk effects and multivariate logistic regression analysis
was applied to assess age, gender and APOE
 4-adjusted risk effects. Non-parametric
Mann-Whitney U and one-way ANOVA tests were used to investigate differences in CSF
42, tau or p-tau levels with respect to the studied SNPs. The haploview 4.2 program was
utilized for pairwise linkage disequilibrium and haplotype block structure analyses (Barrett
et al., 2005). The target gene option in the miRWalk database was used to assess the
predicted miRNA binding sites in the NR1H3 gene (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/predictedmirnagene.html). Power determinations were
implemented using nQuery Advisor release 4.0 software. The p-values were adjusted for
multiple comparisons by multiplying them with the number of SNPs studied (Bonferroni
correction). Association analysis of four family-based sample sets was conducted by an
extension (Won et al., 2009) of the family-based association test (FBAT) method
implemented in PBAT version 3.6 (Lange et al., 2004). Meta-analysis with the statistical
package METAL (Willer et al., 2010) (http://www.sph.umich.edu/csg/abecasis/Metal) was
performed to assess an overall p-value from a weighted sum of the statistics of individual
studies including one Finnish AD case – control –cohort and four family-based cohorts
from USA. In functional studies, one-way analysis of variance (ANOVA), followed by
Fisher's least significant difference (LSD) post-hoc test was used in experiments with more
than one variable. In experiments with only one variable, an independent-sample t test
(equal variances assumed) or Mann-Whitney U test (equal variance not assumed) was used
to test statistical significance between the sample groups. Correlations were assessed using
Pearson’s two-tailed correlation analysis. All values are reported as means ± standard
deviation (SD) or standard error of mean (SEM). The level of statistical significance was
defined as p < 0.05.
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5 Results
5.1 GENETIC ASSESSMENT OF GENES INVOLVED IN A DEGRADATION
IN AD
The most common, late-onset form of AD has been suggested to be caused by deficits in A
clearance or degradation (Mawuenyega et al., 2010). In this study, 12 genes known to be
involved in A clearance or degradation were selected to elucidate the effects of genetic
variation of these genes on disease association, age of onset, and CSF biomarker levels. The
Finnish AD case-control cohort used in this study consisted of 642 patients with probable
AD and 682 age-matched healthy control subjects. Genes for this study (MMEL1, ECE1,
ECE2, AGER, PLG, PLAT, NR1H3, MMP3, LRP1, TTR, NR1H2, and MMP9) were selected on
the basis of PubMed-based literature search. Genes encoding well-known A-degrading
enzymes IDE, NEP and high temperature requirement 1 (HTRA1) were investigated
previously using the same sample cohort and thus they were excluded from this study
(Vepsalainen et al., 2007; Helisalmi et al., 2004; Vepsalainen et al., 2009; Turunen et al.,
2011). The single nucleotide polymorphisms (SNPs) were selected on the basis of haplotype
block structure to capture the genetic information of the entire gene region. All the
genotyped SNPs were found to be in Hardy-Weinberg equilibrium in both AD and control
groups. The distribution of APOE
2/3/4 was 0.04/0.80/0.16 and 0.01/0.54/0.45 in control and
AD groups, respectively. This indicated that APOE
 4 allele was significantly over-
represented among the AD patients (p<0.001, OR=6.00; 95% CI 4.73 to 7.61).
A nominally significant difference in allele distribution was found between AD and control
group with rs1799986 in LRP1 gene encoding low density lipoprotein-related protein 1
(p=0.017). Furthermore, among the T allele carriers, the same rs1799986 SNP was found to
have ~1.3 fold risk according to both univariate and APOE, gender and age –adjusted
multivariate logistic regression analyses (Table 15).
Kaplan-Meier survival analysis revealed a decline in the age of onset among AD patients
carrying the A allele of rs723744 [CA+AA = 70.8 years (95% CI 69.9-71.6) vs. CC = 71.7 years
(95% CI 70.9-72.5), p=0.011] and the C allele of rs3794884 [(AC+CC = 71.0 years (95% CI 70.1-
71.8) vs. AA = 71.8 years (95% CI 71.0-72.6), p=0.039] in the TTR gene encoding
Transthyretin (Table 15). In line with this finding, the G allele carriers of rs1080093 in TTR
gene (GG+GC vs. CC; p=0.01) demonstrated an elevation in CSF p-tau levels (Table 15).
In addition, the levels of t-tau in CSF were decreased among AD patients carrying the T
allele of rs2236847 (TT+TC vs. CC; p=0.03) in the ECE1 gene encoding endothelin converting
enzyme 1. In addition, a decrease at the age of onset was detected among AD patients
carrying the G allele of rs902415 [AG+GG = 70.6 years (95% CI 69.6-71.6) vs. AA = 71.9 years
(95% CI 71.1-72.6), p=0.026] in ECE2 gene encoding endothelin converting enzyme 2.
Multivariate APOE, gender, and age-adjusted logistic regression analyses revealed a
decreased risk of AD for the C allele carriers of rs7120118 in NR1H3 gene encoding LXR
(Table 15). In agreement with this finding, a nominally significant decline in CSF p-tau
levels among AD patients carrying the C allele of rs7120118 in NR1H3 gene was found
(Table 15). The A allele carriers of rs2279238 in the same gene also demonstrated reduced p-
tau levels in the CSF. Interestingly, the individual genotypes of rs7120118 exhibited a gene
dose-dependent decrease of CSF t-tau and p-tau levels among AD patients carrying the C
allele (p=0.034 and p=0.023, respectively) (Table 15). The rs2279238 also revealed a gene
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dose-dependent decline in p-tau (p=0.016), but not in t-tau (p=0.075) levels among AD
patients carrying the A allele.
In summary, the most interesting findings were observed in the genetic variation in LRP1,
TTR and NR1H3 genes, which revealed nominally significant results when analysing allele
distribution, risk effects, age of onset and CSF biomarker levels. These findings are
summarized in Table 15.
Table 15. Summary of the most interesting findings of study I
RISK EFFECT
(logistic regression)
GENE /
POLYMORPHISM
Univariate Multivariate
(gender, age and APOE
adjusted)
AoO CSF
p-tau
Model OR (95% CI) p* OR (95% CI) p* p* p*
NR1H3
rs12221497 GA+AA vs GG 0.82(0.63-1.08) 0.16  0.86(0.63-1.17) 0.33 0.15 0.92
rs2279238 GA+AA vs GG 1.02(0.81-1.29) 0.87  0.88(0.67-1.15) 0.34 0.45 0.020
rs7120118  TC+CC vs TT 0.81(0.63-1.03) 0.09  0.70(0.53-0.93) 0.014 0.94 0.011
LRP1
rs4759275  GA+AA vs GG 1.00(0.79-1.25) 0.98  1.03(0.80-1.34) 0.82 0.73 0.11
rs1799986  CT+TT vs CC 1.31(1.03-1.66) 0.027  1.33(1.01-1.74) 0.040 0.69 0.24
rs1800139  TC+CC vs TT 1.23(0.98-1.55) 0.08  1.26(0.97-1.64) 0.09 0.64 0.43
TTR
rs723744 CA+AA vs CC 1.04(0.84-1.30) 0.72  1.00(0.77-1.28) 0.97 0.011 0.21
rs1080093  CG+GG vs CC 1.17(0.93-1.47) 0.18  1.11(0.85-1.44) 0.44 0.13 0.010
rs3794884 AC+CC vs AA 1.07(0.84-1.35) 0.59  1.01(0.78-1.32) 0.93 0.039 0.19
OR, Odds ratio; CI, Confidence Interval; AoO, Age of Onset; CSF p-tau, cerebrospinal fluid phospho-tau
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5.2 EFFECTS OF VARIATION IN NR1H3 GENE ON THE EXPRESSION OF
LIVER-X-RECEPTOR  AND THE PROGRESSION OF AD
NR1H3 (nuclear receptor subfamily 1, group H, member 3) is a gene encoding LXR, a
transcription factor controlling the expression of APOE and lipid transporter genes ABCA1
and ABCG1 (Beaven and Tontonoz, 2006). Interestingly, in an AD mouse model agonists of
LXR have been shown to increase APOE-dependent A clearance (Jiang et al., 2008). In
study I, the genetic variation in NR1H3 gene exerted prominent effects on the risk of AD.
Thus, it was decided to assess the effects of rs7120118 variation in NR1H3 on the expression
of NR1H3, APOE, ABCA1, and ABCG1 as well as on the levels of soluble A42 and -
secretase activity in the inferior temporal cortex of subjects with different stages of AD-
related neurofibrillary pathology. These neuropathological samples were subdivided into
three severity groups: mild (stages = 0-2), moderate (stages = 3 and 4), and severe (stages = 5
and 6) according to Braak staging.
Before investigating the genetic effects of NR1H3 gene variations, biochemical
characterization of brain samples were conducted with an assessment of genetic variation
in APOE. This characterization revealed augmentation in -secretase activity and levels of
soluble A42 with respect to disease severity. As expected, CSF A42 levels showed a
reduction whereas CSF tot-tau and p-tau levels demonstrated an increase with respect to
disease severity. Furthermore, there was a negative correlation between the levels of CSF
A42 and soluble A42 in the inferior temporal cortex. The carriers of APOE
4, the major
risk factor in sporadic AD, were found to be significantly overrepresented in the moderate
and particularly in the severe group where ~85% of subjects were carrying the 4 allele. The
presence of the APOE
 4 allele also increased both soluble A42 levels and -secretase
activity in a dose-dependent manner. In other words, subjects with the 44 genotype
showed a more robust increase in these parameters than those with the 34 genotype when
compared to the 33 genotype. The number of APOE
 4 alleles did not affect the APOE
mRNA levels as measured by qPCR.
Since these assessments validated the sample set, the next experiment evaluated the effects
of the rs7120118 variation in the NR1H3 gene  on  the  progression  of  AD  and  A-related
measurements. The distributions of rs7120118 T/C alleles and TT/CT/CC genotypes were
0.59/0.41 and 0.38/0.42/0.20, respectively, which are in line with the result obtained in study
I. The rs7120118 CC genotype was found to be underrepresented in the severe group,
although this result did not reach statistical significance. In agreement, the soluble A42
levels were significantly reduced in those patients with the CC genotype of rs7120118 as
compared to the TT genotype. There was no alteration in -secretase activity or CSF A42
levels with respect to the rs7120118 genotype.
Before addressing the ultimate question whether rs7120118 variation affects the expression
of NR1H3, ABCA1, ABCG1, and APOE, the effect of the disease severity was assessed on the
expression of those genes. qPCR analysis did not reveal significant alterations in the mRNA
levels of NR1H3, ABCA1, ABCG1, and APOE with respect to disease severity. Subsequent
qPCR analysis, in turn, revealed a significant increase in the mRNA levels of NR1H3 among
AD patients with the CT genotype of rs7120118 as compared to TT genotype.
In summary, biochemical characterization and assessment of the effects of genetic variation
in APOE revealed that this brain sample set had been valid to permit further assessments.
Moreover, these data suggest that the CC genotype of rs7120118 reduces soluble A42
levels while the CT genotype of rs7120118 associates with increased NR1H3 mRNA levels
in the inferior temporal cortex.
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5.3 ELUCIDATION OF THE BACE1 REGULATING FACTOR GGA3 IN
ALZHEIMER’S DISEASE
Several studies have shown that Golgi-localized -ear-containing ADP-ribosylation factor-
binding protein 3 (GGA3) plays a potential role in AD pathogenesis by regulating the
intracellular trafficking and degradation of BACE1 (Tesco et al., 2007; Kang et al., 2010;
Sarajärvi et al., 2009). This study investigated the functional role of tau, BACE1, GGA3 and
phosphorylated eIF2 (p-eIF2, phosphorylated at Ser51), a factor regulating translation of
BACE1 (O'Connor et al., 2008) in two AD brain sample sets. The first set consisted of
temporal cortex samples from AD patients and healthy controls, while the second set
contained inferior temporal cortex samples from patients with different degrees of AD-
related neurofibrillary pathology. Furthermore, the genetic role of GGA3 was elucidated
using Finnish AD case-control cohort and four independent family-based sample sets.
5.3.1 Assessment of BACE1, GGA3, p-eIF2 and tau levels in two AD brain sample sets
First, the expression of GGA3, BACE1 and p-eIF2 was investigated using the AD case-
control sample set. In the temporal cortex of AD patients, protein levels of GGA3 were
decreased while protein levels of BACE1 and p-eIF2 were augmented as compared to
controls. These findings are in agreement with previous studies (Tesco et al., 2007;
O'Connor et al., 2008). Next, a second sample set consisting of 24 inferior temporal cortex
samples was subdivided into three groups according to Braak staging; mild (stages 0-2,),
moderate (stages 3-4) and severe (stages 5-6) (Braak et al., 2006a) and p-tau levels were
analyzed in protein extracts from the brain samples using the AT8 antibody in Western
blot. This antibody recognizes tau phosphorylated at Ser202/Thr205 residues, which are
two important AD-related phosphoepitopes. The AT8 staining revealed ~2 fold and ~8 fold
increases in tau phosphorylation in the moderate and severe groups as compared to the
mild group. This finding is in line with the data from immunohistological staining of brain
samples with the same AT8 antibody; they also confirmed that protein extraction had been
conducted properly. Subsequently, it was decided to assess how the progression stage of
AD would affect GGA3 expression in the inferior temporal cortex. qPCR and Western blot
analysis did not reveal significant alterations in GGA3 mRNA or protein levels with respect
to the progression of the disease. However, protein levels of p-eIF2 were increased by
~50% in the severe group as compared to both mild and moderate groups. Unexpectedly,
BACE1 protein levels showed a slight decrease in the severe group as compared to the
moderate group. However, -secretase activity and soluble A42 levels were elevated in
parallel with the severity of the disease. Next it was decided to investigate whether there
was a relationship between the different factors analyzed in AD brain samples. No
significant correlation was found between BACE1 and GGA3 or between BACE1 and p-
eIF2 protein levels. Interestingly, a strong positive correlation was found between p-eIF2
and p-tau and between GGA3 and total-tau. Correlation analysis also revealed a positive
correlation between p-tau and -secretase activity and between p-tau and soluble A42
levels. No correlation was detected between long PMDs and GGA3 or BACE1 protein
levels, suggesting that post-mortem-related degradation processes did not influence the
results.
5.3.2 Genetic assessment does not support a persistent risk effect for GGA3
polymorphisms in AD
In addition to the assessment of expression level, the association of genetic variation in
GGA3 gene with AD was analyzed using the Finnish AD case-control sample set and four
independent family-based AD cohorts originating from USA. A nominally significant
genotype and allele association with AD was observed with the GGA3 SNPs rs2242230 and
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rs9988 in the Finnish AD case-control cohort. However, after Bonferroni correction for
multiple comparisons, only the allelic association of rs2242230 with AD remained
significant (p=0.04). Univariate and multivariate (APOE-, gender-, and age-adjusted)
logistic regression analyses showed a decreased risk for the A allele carriers of rs2242230,
which remained significant after Bonferroni correction (p=0.03 and p=0.02, univariate and
multivariate, respectively). Furthermore, association analysis revealed the A-C-C-T
haplotype for SNPs rs2242230, rs11077781, rs9988, and rs2291031, which was significantly
over-represented in the control group (p=0.01). None of the studied SNPs revealed any
significant alterations in A42, tot-tau or p-tau levels in the CSF or any changes in Kaplan-
Meier age of onset analysis. Analysis of GGA3 gene region in four family-based AD sample
sets revealed the most significant association with SNPs rs17568408, rs1471454 and
rs78740665 with the affection status in the NIMH cohort. However, these associations were
not replicated in the three other cohorts (NCRAD, NIA-LOAD and CAG). SNPs rs1471454
and rs9988 were analyzed in the Finnish case-control and four family-based cohorts.
However, meta-analysis of these two SNPs did not reveal any significant association. The
most significant meta-analysis result was obtained with the age of onset phenotype in the
family-based sample sets for rs9988 (meta p=0.002).
5.3.3 rs2242230 polymorphism in GGA3 gene does not affect GGA3 expression in the
inferior temporal cortex of AD patients
Finally, since rs2242230 polymorphism had a nominally significant effect on the risk of AD
in the Finnish AD case-control cohort, it was decided to assess whether the rs2242230
variation would affect the GGA3 expression levels in inferior temporal cortex AD brain
sample set. The distribution of GG/GA/AA genotypes for rs 2242230 variation in the brain
sample set was 0.83/0.17/0.00, which is in line with the distribution of these genotypes
observed in the clinical sample set among AD patients in this study. However, no
significant alteration in GGA3 mRNA or protein levels was observed in the brain samples
with respect to the rs2242230 polymorphism. Moreover, the rs2242230 variation in GGA3
gene revealed no significant effect on -secretase activity, BACE1 protein levels, or soluble
A42 levels.
5.4 IN VITRO AND IN VIVO STUDIES ON THE RELATIONSHIP BETWEEN
UBIQUILIN-1 AND BACE1
5.4.1 Ubiquilin-1 expression is decreased with respect to the severity of AD
Ubiquilin-1 has been shown to associate with AD at both the genetic and functional levels
and this may indicate an involvement in APP processing and degradation (Bertram et al.,
2005; Stieren et al., 2011; Hiltunen et al., 2006). Study IV investigated ubiquilin-1 expression
in human AD brain and effects of ubiquilin-1 on BACE1 using in vitro cell culture models
and an AD mouse model in vivo using lentivirus-mediated ubiquilin-1 overexpression.
Ubiquilin-1 mRNA levels were assessed from 60 RNA samples extracted from the inferior
temporal cortex of AD subjects. This assessment revealed a trend towards a global decrease
in ubiquilin-1 expression with respect to the disease progression. Accordingly, Western blot
analysis showed a trend towards a decrease in ubiquilin-1 protein levels according to the
progression of AD. Altogether, these findings indicate that ubiquilin-1 levels are altered in
human AD brain. Furthermore, correlation analysis revealed a trend towards a positive
correlation between ubiquilin-1 and BACE1 protein levels in human brain samples, which
prompted further study of the relationship between ubiquilin-1 and BACE1 in AD model
systems.
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5.4.2 Overexpression of ubiquilin-1 increases BACE1 levels in in vitro models by
delaying the degradation of BACE1
Human neuroglioma cells (H4 TV1-13, (Lu et al., 2009)) stably overexpressing  the full-
length ubiquilin-1 TV1 by ~2.5-fold as compared to control cells (H4 pcDNA-A) were used
to investigate the effects of ubiquilin-1 on BACE1 expression in more detail. Since the
endogenous BACE1 protein levels in H4 cells are almost undetectable, H4 TV1-13 and
control cells were transfected with three different BACE1 plasmids: BACE1 plasmid
containing cytomegalovirus (CMV) promoter but lacking endogenous 5’UTR or 3’UTR
BACE1 regulatory regions (BACE1-myc), BACE1 plasmid with the endogenous promoter
containing 5’UTR and 3’UTR (5’3’UTR-BACE1) or BACE1 plasmid with the endogenous
promoter but containing 5’UTR only (5’UTR-BACE1). The quantification of BACE1 levels
24 h after transfection revealed ~1.7 fold, ~3.3 fold and ~4.0 fold increases with BACE1-myc,
5’UTR-BACE1 and 5’3’UTR-BACE1, respectively, as compared to control samples. To
confirm that ubiquilin-1 does not increase the expression also of other proteins in an non-
specific manner, H4 TV1-13 and control cells were transfected with EGFP plasmid. No
alteration was observed in EGFP levels between H4 TV1-13 and control cells.
Next, the effects of transient overexpression of ubiquilin-1 were studied in H4 cells stably
overexpressing APP751. Co-transfection with 5’3’UTR-BACE1 and ubiquilin-1 TV1
plasmids elevated both ubiquilin-1 and BACE1 levels by ~3.5 fold as compared to control
cells transfected with 5’3’UTR-BACE1 and empty control plasmid. This experiment was
replicated by co-transfecting human neuroblastoma cells (SH-SY5Y) stably overexpressing
APP751 with 5’3’UTR-BACE1 and ubiquilin-1 TV1 plasmids. The replication showed a
similar outcome as in H4 cells, increasing ubiquilin-1 levels by ~4.5 fold and BACE1 levels
by ~2.5 fold as compared to control cells. Since endogenous BACE1 could be detected in
these cells, the next experiment determined whether transient overexpression of ubiquilin-1
TV1 in SH-SY5Y-APP751 cells would affect endogenous BACE1 levels. However,
overexpression of ubiquilin-1 TV1 was not observed to significantly influence endogenous
BACE1 levels.
In order to investigate the underlying mechanism how ubiquilin-1 may affect BACE1
expression, it was examined whether overexpression of ubiquilin-1 could regulate the
levels of well-known factors involved in intracellular trafficking of BACE1. The protein
levels of GGA1, GGA3, ARF6 and Seladin-1/DHCR24 were assessed in SH-SY5Y-APP751
cells cotransfected with 5’3’UTR-BACE1 and ubiquilin-1 TV1 and these values compared
those in cells transfected with 5’3’UTR-BACE1 and control plasmids; no significant
alterations were detected. Furthermore, no changes were observed in lysine63 or lysine48 –
linked ubiquitination of BACE1 after immunoprecipitation in these same samples.
However, the cycloheximide time-course assay revealed that the half-life of BACE1 had
been significantly increased in H4 TV1-13 cells transfected with 5’3’UTR-BACE1 in
comparison to the levels in control cells, suggesting that ubiquilin-1 might modify BACE1
degradation or subcellular localization. Interestingly, cell imaging studies have revealed
that overexpression of ubiquilin-1 could influence the subcellular localization of BACE1 in
SH-SY5Y-APP751 cells. Myc-TV1 overexpression significantly decreased BACE1
colocalization with Rab7, a marker for late endosomes/lysosomes (LEL), when compared to
control cells. It was also observed that there was a simultaneous increase in BACE1
colocalization with TfR, a marker for early and recycling endosomes, and EEA1, a marker
for early endosomes, in cells co-overexpressing myc-TV1 as compared to control cells, but
these increases did not reach statistical significance. However, these findings suggest that
ubiquilin-1 may interfere with BACE1 intracellular trafficking and thus modulate the
BACE1 protein levels.
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5.4.3 Lentiviral ubiquilin-1 gene delivery does not affect the maturation of APP but
slightly increases BACE1 protein levels in the hippocampus of APP/PS1 mice
To investigate the effects of ubiquilin-1 on the endogenously expressed BACE1 in vivo,
lentivirus vector encoding ubiquilin-1 TV1 (LV-TV1, n=8) or control vector encoding GFP
(LV-GFP, n=8) was bilaterally injected into the hippocampus of 5-month old APP/PS1
transgenic mice. After 4.5 months, the animals were sacrificed and the right hemisphere
was taken for immunohistochemical analysis and the left hemisphere was dissected into
hippocampal and cortical samples for biochemical analyses. Western blot using human-
specific ubiquilin-1 antibody showed a strong ubiquilin-1 expression in the hippocampus
but not in the dorsal cortex samples of the LV-TV1 mice. Western blot analysis also showed
strong GFP expression in the hippocampus but not in the dorsal cortex of LV-GFP treated
mice. Immunohistochemical analysis of samples from LV-TV1 mice and fluorescence
microscopy analysis of samples from LV-GFP mice revealed intense ubiquilin-1 and GFP
expression, respectively, particularly in dentate gyrus area of hippocampus. In summary,
these data indicated that the lentivirus-mediated transfer of ubiquilin-1 and GFP in vivo had
been successfully achieved.
Immunohistochemical analysis revealed a trend towards a decrease in A load in LT-TV1
mice in comparison to the control mice. The ELISA assay detected an elevation in both
soluble and insoluble A40 as well as soluble A42 levels in LT-TV1 samples as compared
to controls. These alterations in the -amyloid load or in soluble or insoluble A40 or A42
levels were not statistically significant, but they were consistently detected. Ubiquilin-1
gene delivery did not significantly affect the levels of mature or immature forms of APP or
the ratio of mature and immature APP in vivo. Lentivirus-mediated overexpression of
ubiquilin-1 was not observed to significantly affect the levels of inflammatory markers,
such as glial fibrillary acidic protein (GFAP) levels or activation of microglia and
macrophages as detected by CD45 staining. Finally, it was decided to assess whether
lentiviral gene delivery of ubiquilin-1 had changed BACE1 expression in hippocampus of
APP/PS1 mice. A slight, but not statistically significant, increase in BACE1 protein levels
and -secretase activity was found in the hippocampus of LT-TV1 mice as compared to
controls, which is in line with the in vitro findings. In addition, a significant correlation was
found between -secretase activity and both soluble A40 and soluble A42.
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6 Discussion
6.1 ROLE OF GENES INVOLVED IN A DEGRADATION AND CLEARANCE
IN AD AMONG FINNISH POPULATION
AD has been hypothesized to orginate from the abnormal accumulation of aggregation-
prone A –peptide, which in LOAD has been postulated to be caused by defects in A
clearance or degradation. Study I examined 12 genes which are known to encode enzymes
or proteins participating in the A catabolism on the basis of a literature search, and
elucidated their genetic role in AD. Based on the SNP screening, the genetic variation in the
LRP1 gene showed a nominally significant allele association with AD and increased the risk
of the disease. These effects were found with the rs1799986 variation, which has been
extensively studied in several AD case-control sample sets and in one family-based cohort
(www.alzgene.org, (Bertram et al., 2007). LRP1 has an important biological role in the
receptor-mediated clearance of A from brain to periphery through the blood brain barrier
(Tanzi et al., 2004), which emphasizes the importance of further assessments of the genetic
role of LRP1 in different ethnic cohorts.
Polymorphisms in the TTR gene, in turn, were associated with a significant increase in CSF
p-tau levels (G allele carriers of rs1080093) and also a significant decrease in the age of onset
(A allele carriers of rs723744 and C allele carriers of rs3794884). Transthyretin is a potent
participant in degradation and clearance of A, since it binds to A in the CSF and thus
decreases A aggregation (Schwarzman et al., 1994). Recently, it was shown that
transthyretin is able to proteolytically cleave A at multiple sites (Costa et al., 2008).
Furthermore, overexpression of transthyretin was able to confer protection in APP23 AD
mice from both the A toxicity and the subsequent behavioral impairment (Buxbaum et al.,
2008), further suggesting that transthyretin has neuroprotective effects.
Moreover, polymorphism in NR1H3 affected the risk of AD as the C allele carriers of
rs7120118 in NR1H3 displayed a protective effect against AD. This observation is supported
by the finding that both C allele carriers of rs7120118 and A allele carriers of rs2279238
exhibited a gene dose-dependent decrease in CSF p-tau levels. LXR encoded by NR1H3 is
a ligand-activated transcription factor expressed in the brain (Wang et al., 2002). It induces
the expression of the ATP-binding cassette transporters A1 and G1 (ABCA1 and ABCG1)
and APOE (Beaven and Tontonoz, 2006). Importantly, activation of LXR leads to the
elevation of lipidated forms of APOE, which have been shown to reduce the levels of A
and numbers of plaques in a mouse model of AD (Jiang et al., 2008). The mechanism of this
effect was elucidated to be an agonist-induced activation of LXR which increased the
levels of lipidated APOE and enhanced the intracellular degradation of soluble A by
microglia (Jiang et al., 2008).
In spite of the interesting findings obtained with LRP1, TTR and NR1H3 genes, none of the
results remained statistically significant after adjusting the p-values for multiple
comparisons. Furthermore, recent GWA or meta-analysis studies have not revealed
significant associations between LRP1, TTR and NR1H3 genes with AD (Harold et al., 2009;
Lambert et al., 2009; Lambert et al., 2011; Naj et al., 2011). In summary, these results
therefore suggest that genetic variations in MMEL1, ECE1, ECE2, AGER, PLG, PLAT,
NR1H3, MMP3, LRP1, TTR, NR1H2, and MMP9 genes do not exert any significant effects
on the AD risk among the Finnish case-control –cohort.
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6.2 THE CC GENOTYPE OF rs7120118 IN NR1H3 GENE ASSOCIATES
WITH DECREASED SOLUBLE A42 LEVELS
Previous studies have shown that LXR and its obligatory partner RXR are potential drug
targets in AD, as they augment the APOE-mediated A clearance from the brain (Jiang et
al., 2008; Cramer et al., 2012). Thus, it is essential to assess the effects of genetic alterations
in NR1H3 on the expression of LXR or its downstream targets. Despite the fact that the
effects of the observed polymorphism in NR1H3 did not remain statistically significant after
adjusting the p value for multiple comparisons in study I, the initial data suggested that the
genetic variation in NR1H3 gene may modulate the risk of AD. Prompted by these data, it
was decided to investigate the effects of rs7120118 variation on the expression of NR1H3,
APOE, ABCA1 and ABCG1, the levels of soluble A42, and -secretase activity using a
sample set consisting of inferior temporal cortex samples of patients with different degree
of AD-related neurofibrillary pathology. The rs7120118 variation was chosen for this study
as in study I the C allele carriers of this SNP were found to have a reduced risk of suffering
AD. Furthermore, in agreement with having a protective effect, the C allele of rs7120118
decreased CSF tot-tau and p-tau levels in a dose-dependent manner among the AD
patients.
Biochemical characterization of the inferior temporal cortex samples revealed that soluble
42 levels and -secretase activity were increased with respect to the progression of
neurofibrillary pathology (mild, moderate, and severe). These findings are in line with
previous studies reporting that soluble, nonfibrillar A levels (Lue et al., 1999; McLean et
al., 1999; Wang et al., 1999) and -secretase activity (Fukumoto et al., 2002; Holsinger et al.,
2002; Li et al., 2004; Tyler et al., 2002; Yang et al., 2003) are augmented in AD brain samples
as compared to healthy controls. Furthermore, the statistically significant correlation was
observed between -secretase activity and soluble A42 levels, which is an expected
outcome since -secretase is the rate-limiting enzyme in A production. CSF A42, tot-tau
and p-tau levels, biomarkers applied in the clinical diagnosis of AD, were available from a
subset of patients. CSF A42 levels were found to be significantly decreased, while the tot-
tau and p-tau levels displayed a significant elevation with respect to the progression of
neurofibrillary pathology. These findings are in agreement with several previous studies
showing that A42 levels are decreased whereas tot-tau and p-tau are increased in the CSF
of AD patients as compared to healthy controls (Blennow, 2004). In addition, there was a
significant negative correlation between CSF A42 levels and soluble A42 levels in the
temporal cortex. In summary, these findings validated the brain samples for subsequent
assessments.
Before assessing the effects of variation in NR1H3, the samples were evaluated with respect
to the major genetic risk factor of AD, the APOE
4 allele. As expected, APOE
4 carriers
were overrepresented in the moderate, particularly in the severe group of this study. The
soluble A42 levels were found to be increased in a dose-dependent manner with the
number of APOE
4 alleles. This also was an expected outcome since it has been shown that
APOE
4 allele increases the deposition of A in the cerebral cortex of AD brain (Schmechel
et al., 1993). There was a trend towards an increase in APOE mRNA levels among the
subjects with two copies of APOE 4 allele as compared to subjects with one 4 or with no
4 allele. Previously levels of APOE mRNA in the brain with respect to the APOE genotype
have not been widely studied. However, one study has reported an elevation in APOE
mRNA levels in the temporal cortex of AD patients carrying the APOE
4 allele (Yamagata
et al., 2001). Overall, these findings are in agreement with previous reports and thus
validate the brain sample set also with respect to APOE.
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The distribution of the rs7120118 genotypes indicated that the CC genotype was
underrepresented in the severe group, which agrees with the results of study I i.e. a
protective effect for the C allele carriers of rs7120118. However, there were proportionally
more CC genotypes in the moderate group as compared to the mild group, leading to the
situation that there was no statistically significant alteration in the distribution of the
rs7120118 genotypes. Interestingly, soluble A42 levels in the brain samples were decreased
among subjects with rs7120118 CC genotype as compared to the TT genotype, which
strongly supports the concept of a protective effect for the C allele. The fact that -secretase
activity was not affected by the rs7120118 variation is in agreement with the results of Jiang
et al. who reported that the effect of NR1H3 / LXRa on soluble A levels was due to
augmented degradation rather than to decreased A production (Jiang et al., 2008). The
ultimate goal of the study was to investigate whether rs7120118 variation would affect the
expression of NR1H3 or its downstream targets ABCA1, ABCG1 or APOE. The progression
of neurofibrillary pathology did not affect the expression of NR1H3, ABCA1, ABCG1 or
APOE. Thus, it was decided to proceed with the assessment of the effect of rs7120118
variation on the expression of these genes.
Interestingly, there was a significant increase in the levels of NR1H3 mRNA in those
subjects with the rs7120118 CT genotype as compared to the TT genotype. However, the CC
genotype of rs7120118 associated with unchanged mRNA levels of NR1H3 as compared to
TT genotype. Moreover, since the rs7120118 variation had no effect on the expression of the
downstream targets of LXR ABCA1, ABCG1 or APOE, it is questionable whether the
augmented expression levels of NR1H3 observed with the rs7120118 CT genotype have any
biological relevance. However, there was a significant positive correlation between the
mRNA levels of NR1H3, ABCA1, ABCG1, and APOE, which indicates that at the individual
level, changes in the expression of NR1H3 may be consequently reflected in the expression
of its downstream targets. Long post-mortem delays did not correlate with reduced RNA
quality. Furthermore, the variation in the RNA quality did not correlate with altered
NR1H3 expression, suggesting that post-mortem-related degradation processes had not
significantly affected the observed results.
Since LXR has a crucial role in cholesterol metabolism (Kapur et al., 2008) and also in
inflammation (Joseph et al., 2003), it is obvious that there must be a complex regulatory
system to control the activation and/or expression of LXR. Indeed, a recent study
described a mechanism through which LXR autoregulates its own expression via the
induction of SREBP-1c, which in turn upregulates miRNA hsa-miR-613 (Ou et al., 2011).
The binding site of this specific miRNA is located at the 3’UTR of NR1H3 and it is able to
repress the expression of LXR. A search through the miRWalk database revealed 25
predicted miRNA binding sites in the 3’UTR of NR1H3. In fact, SNP rs375078947 was found
to be located immediately next to the 5’ end of the binding site of miRNA hsa-miR-613,
suggesting that this polymorphism may affect the binding affinity of this miRNA to
NR1H3. rs7120118, the SNP of interest in this study is located in the same haplotype block
with rs375078947 and with the binding site of validated hsa-miR-613. Thus, it is tempting to
speculate that rs7120118 variation could affect the binding of hsa-miR-613 and other
putative miRNAs to NR1H3 and hence affect the expression of LXR.
LXR has been widely studied during recent years and it has been claimed to be a potential
drug target not only in AD but also in hypercholesterolemia (Kapur et al., 2008). Several
agonists of LXR have been tested in animal models of AD and they have shown
prominent effects by decreasing the brain A levels and the plaque burden, reducing
inflammation and reversing the memory impairment (Mandrekar-Colucci and Landreth,
2011). Unfortunately, long-term treatments with existing LXR agonists have evoked to
severe side effects, such as hepatic steatosis, and this has prevented these drugs from
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undergoing clinical trials. However, the investigations of LXR agonists have revealed the
important functional link between the most significant genetic risk factor of AD, APOE, and
the clearance of A.
6.3 GGA3 AND p-eIF2 ARE INVOLVED IN THE REGULATION OF BACE1
Study III attempted to elucidate the functional role of GGA3 and p-eIF2 in the regulation
of BACE1 using two different AD brain sample sets. Furthermore, the genetic role of GGA3
was investigated in the Finnish AD case control cohort and four independent family-based
sample sets. Clarification of the functional role of GGA3, BACE1 and p-eIF2 using AD
case-control brain sample set revealed a reduction of GGA3 protein levels simultaneously
with increased BACE1 and p-eIF2 levels in the temporal cortex of AD patients as
compared to healthy controls. These findings are in line with previous studies which have
also reported a decrease in the GGA3 levels (Tesco et al., 2007) and an elevation of those of
BACE1 (Fukumoto et al., 2002; Holsinger et al., 2002; Li et al., 2004; Tyler et al., 2002; Yang
et al., 2003) and p-eIF2 (O'Connor et al., 2008) in AD brain as compared to age-matched-
controls. Findings from this sample set conform with the concept that decreased GGA3
levels can cause inhibited transport of BACE1 to lysosomes for degradation, which leads to
augmented BACE1 levels (Tesco et al., 2007). It has been shown that under apoptotic
conditions, GGA3 undergoes caspase-mediated cleavage leading to decreased GGA3 levels,
stabilization of BACE1 to endosomes and increased A production (Sarajärvi et al., 2009).
In parallel with the decreased GGA3 levels, increased phosphorylation of eIF2 has been
demonstrated to increase the translation and the protein levels of BACE1 (O'Connor et al.,
2008).
We also evaluated GGA3, BACE1 and p-eIF2 levels in a subset of brain samples with
AD-related neurofibrillary pathology used in study II. These were subdivided into three
severity groups according to Braak staging (Braak et al., 2006a). First, p-tau levels were
analyzed in protein extracts of brain samples using AT8 antibody by Western blotting. The
observed gradual increase of p-tau levels with respect to disease progression is in
agreement with previous studies and is consistent with the immunohistological
characterization of brain sections from the same sample set and therefore this validated the
preparation of the protein lysates conducted in this study.
Subsequent analysis of brain samples revealed no alterations in GGA3 mRNA or protein
levels with respect to the progression of the disease. Protein levels of p-eIF2, in turn, were
significantly increased in the severe group in comparison to both mild and moderate
groups, suggesting that phosphorylation status of eIF2 may be a better indicator of the
disease progression than the GGA3 levels. The decrease of BACE1 protein levels in the
severe group was an unexpected outcome, particularly when -secretase activity and
soluble A42 levels were at the same time gradually elevated with respect to the severity of
the disease. There was no correlation between PMDs and GGA3 or BACE1 protein levels,
indicating that post-mortem-related degradation processes did not significantly modify
these results.
Correlation analyses did not reveal any correlation between BACE1/-secretase activity
and GGA3 or between BACE1/-secretase activity and p-eIF2 protein levels in the inferior
temporal cortex of AD subjects. Despite the fact that one would have expected to see
correlations between these factors mentioned above, there is one previous study also
reporting no correlation between GGA3 and BACE1 in the frontal cortex of AD patients
(Santosa et al., 2011). Interestingly, a strong positive correlation between p-eIF2 and p-tau
protein levels was found here, although a specific pathway that would connect these two
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factors has not been described thus far. However, there is a study describing intense
immunoreactivity and co-localization of p-eIF2 and p-tau in the hippocampal neurons of
AD patients, while the controls showed only subtle p-eIF2 staining. Young individuals
did not show p-eIF2 staining at all (Chang et al., 2002). Furthermore, another
immunohistological study has reported an association of pancreatic ER kinase (PERK), an
activating kinase of eIF2, with p-tau in hippocampal AD neurons (Hoozemans et al.,
2009). Co-localization of PERK and glycogen synthase kinase 3 (GSK-3), a major tau
kinase, was also observed in AD hippocampus in the same study (Hoozemans et al., 2009).
Overall, these results propose that phosphorylation of eIF2 might affect AD pathogenesis
not only via BACE1 regulation but also by affecting phophorylation of tau. The correlation
found between GGA3 and tot-tau levels is also somewhat surprising. No connection
between these two parameters has been reported earlier in the literature. One speculative
explanation could be that both GGA3 and tau are substrates for caspase-3 (Tesco et al.,
2007; Fasulo et al., 2000) and thus increased caspase-3 activity as is found in the apoptotic
conditions prevailing in AD brain could lead to augmented cleavage of both GGA3 and tau.
The  genetic  assessment  of GGA3 in the Finnish population related to the rs2242230
variation revealed a statistically significant risk effect, i.e. ~30% decreased risk for A allele
carriers as compared to non-carriers in both univariate and APOE-, gender-, and age-
adjusted logistic regression analyses. The SNP rs2242230 is part of a large haplotype block
at the 3’ end of the gene, and this block also encompasses SNPs rs78740665, rs11077781,
rs9988, and rs2291031. In the family-based analyses, the most significant association with
the affection status was observed in the NIMH cohort with SNPs rs17568408, rs1471454,
and rs78740665. However, no associations were obtained with these SNPs in the three other
family-based cohorts. Furthermore, rs1471454 did not show any significant association
when analyzed in the Finnish case-control cohort. Meta-analysis of family-based sample
sets indicated that rs9988 could influence the age of onset in AD patients. Interestingly, the
location of rs9988 in the same haplotype block with rs2242230 suggests that variation in this
region  may  modify  the  risk  of  AD.  However,  since  the  association  varied  in  different
cohorts, meta-analysis did not reveal any statistically significant effects. It is possible that
allelic heterogeneity exists in the GGA3 region in AD, which could explain the variation
between the different cohorts and the fact that this region has not been identified in GWAS
studies. Finally, rs2242230 variation in GGA3 did not associate with any alterations in the
mRNA or protein levels of GGA3, suggesting that the variation in rs2242230 does not affect
the  expression  or  stability  of  the  GGA3  protein  in  the  inferior  temporal  cortex  of  AD
patients.
Taken together, these results emphasize the important role of GGA3 and p-eIF2 in the
regulation of BACE1 and suggest that they are functionally involved in cellular processes in
AD pathogenesis in human AD brain. However, results from genetic assessments did not
support the theory that there is a persistent risk effect for GGA3 polymorphisms in AD.
6.4 IN VITRO AND IN VIVO STUDIES ON THE RELATIONSHIP BETWEEN
UBIQUILIN-1 AND BACE1
There are several studies revealing an association between ubiquilin-1 and AD at both the
genetic and the functional level (Bertram et al., 2005; Stieren et al., 2011; Hiltunen et al.,
2006). BACE1, in turn, is the initial and rate-limiting enzyme in A production and thus
plays a crucial role in AD pathogenesis (Vassar et al., 1999). Furthermore, levels of BACE1
and its activity are thought to increase in AD (Fukumoto et al., 2002; Holsinger et al., 2002;
Li et al., 2004; Tyler et al., 2002; Yang et al., 2003). In addition, BACE1 is currently one of the
leading targets of drug development programmes for AD.  However, recent
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characterizations in BACE1 knockout mice (Willem et al., 2006; Hu et al., 2008; Hu et al.,
2010) and the identification of a number of potential novel BACE1 substrate proteins
(Hemming et al., 2009; Kuhn et al., 2012) may indicate that BACE1 inhibition might cause
adverse side effects and thus complicate BACE1 therapeutic targeting. On the other hand, it
is possible that a suitable therapeutic window can be found by optimal dosing or that
potential side effects may be avoided by careful design of the drug molecules.
Study IV attempted to elucidate the relationship between ubiquilin-1 and BACE1 using the
human post-mortem AD brain sample set, different cell-based in vitro models, and
lentivirus-mediated gene delivery in the brain of AD mice in vivo. Analyses of the inferior
temporal lobe samples from AD brain detected a decrease in both ubiquilin-1 mRNA and
protein levels with respect to the severity of AD as assessed by classification of the
neurofibrillary pathology according to Braak (Braak et al., 2006b). In accordance with this
finding, it had been reported in a previous study that ubiquilin-1 levels declined in the
early phase of AD in the frontal cortex (Stieren et al., 2011). The in vitro experiments
revealed that BACE1 levels were increased in different neuronal human cell lines
transiently or stably overexpressing ubiquilin-1. As expected, the BACE1 construct
containing the potent CMV-promoter showed the highest absolute expression levels,
whereas expression of the BACE1 constructs containing endogenous 5’ and 3’ UTRs
resulted in a more moderate BACE1 overexpression. However, 5’3’UTR BACE1 showed the
highest relative elevation in BACE1 levels in cells with ubiquilin-1 overexpression as
compared to the control cells. The increase of BACE1 levels was observed also in the cells
transfected with the BACE1-myc construct lacking the endogenous UTRs suggests that
ubiquilin-1 affects BACE1 levels through post-translational mechanisms. The levels of
several well-known factors involved in the regulation of intracellular trafficking and
degradation of BACE1 were analyzed in an attempt to elucidate the underlying molecular
mechanisms. However, overexpression of ubiquilin-1 was not found to increase the protein
levels of GGA1, GGA3, ARF6, Seladin-1/DHCR24 or ubiquitination of BACE1 in SH-SY5Y-
APP751. The cycloheximide time-course, in turn, revealed that overexpression of ubiquilin-
1 significantly increased the half-life of BACE1 protein in H4 cells, indicating that
degradation of BACE1 is decreased by ubiquilin-1. This finding evidence that
overexpression of ubiquilin-1 is able to stabilize the BACE1 levels, is supported by the
finding that colocalization of BACE1 with Rab7, a marker for late endosomes and
lysosomes, was also decreased in cells overexpressing ubiquilin-1 as compared to control
cells. It has been shown previously that BACE1 is degraded mainly in the lysosomal
compartment and that GGA3 is a key factor regulating the trafficking of BACE1 from the
endosomes to the lysosomes (Tesco et al., 2007; Kang et al., 2010). Despite the fact that there
was no alteration in GGA3 levels by ubiquilin-1, these data suggest that less BACE1 is
targeted to lysosomal degradation. In summary, the results from in vitro studies indicate
that ubiquilin-1 can affect BACE1 levels at the post-translational level and it stabilizes
BACE1 by directing it away from the lysosomal degradation pathway.
The interrelationship between ubiquilin-1 and BACE1 was examined in vivo by
implementing bilateral lentivirus-mediated gene delivery to the hippocampus of APP/PS1
transgenic mice, since this brain region is crucially involved in memory and learning and is
affected early in AD. This is the first study to utilize a mammalian model organism to
investigate the effects of ubiquilin-1 in vivo. The -amyloid plaque load was found to be
moderately decreased, whereas the levels of soluble A40 and A42 as well as insoluble
40 levels exhibited a trend towards an increase in the hippocampus of ubiquilin-1-
injected mice as compared to control samples. Furthermore, endogenous BACE1 protein
levels and -secretase activity were slightly, but not statistically significantly, increased in
ubiquilin-1-injected animals as compared to controls, which is in accordance with the
findings from the in vitro experiments. As expected, there was a strong positive correlation
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between -secretase activity and soluble A40 and A42 levels. In contrast, the quantified
size of BACE1 immunopositive area was reduced in ubiquilin-1-injected mice as compared
to controls. These contrasting outcomes from analyses of the A plaque load and soluble
 levels may be explained by the constant aggregation and dissolution of A molecules to
and from the plaques; this has been proposed to be a dynamic phenomenon (Maggio et al.,
1992). Furthermore, these results suggest that overexpression of ubiquilin-1 could shift the
balance between the insoluble and soluble forms of A42, which, in turn, might explain the
decreased A plaque load in hippocampus of ubiquilin-1-injected mice.
Overall, the present study revealed that ubiquilin-1 levels were decreased in human brain
according to the severity of AD and that they may correlate with those of BACE1. In vitro
data indicated that overexpression of ubiquilin-1 increases BACE1 protein levels, in
support of the findings obtained in the in vivo experiments. Furthermore, the in vitro studies
demostrated that ubiquilin-1 overexpression resulted in the stabilization of BACE1 due to
decreased degradation in the lysosomal compartment.
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7 Conclusion
The aim of this thesis was to investigate the genetic and functional role of specific genes in
AD by means of molecular genetics using in vitro, in vivo and human post-mortem samples.
Studies I and II were focused on factors involved in A degradation and clearance, whereas
studies III and IV examined the factors regulating BACE1, the initial enzyme in A
production. Based on the results, the following conclusions can be drawn:
1. Genetic analysis of 12 genes (MMEL1, ECE1, ECE2, AGER, PLG, PLAT, NR1H3,
MMP3, LRP1, TTR, NR1H2, and MMP9) known to be involved in A degradation
and clearance revealed nominally significant findings with regard to LRP1, TTR and
NR1H3 genes. However, after adjusting the p-values for multiple comparisons, these
results were not statistically significant, suggesting that genetic variations in these
genes do not have any significant role in AD in the Finnish population.
2. Genetic variation in NR1H3 encoding LXR, a potential drug target in AD, was
found to affect LXR expression and soluble A42 levels in human AD brain, and
may thus modulate the progression of AD.
3. GGA3 has been shown to be involved in the degradation of BACE1, whereas
phosphorylation of eIF2 is involved in the regulation of BACE1 translational level.
Analyses of the two human post-mortem brain sample sets further emphasize the
central functional role of GGA3 and p-eIF2 in the regulation of BACE1. However,
results from genetic assessments do not provide support for a persistent risk effect
for GGA3 variants in AD.
4. Ubiquilin-1  has  been  shown  to  associate  with  AD  in  the  genetic  and in vitro
assessments. Ubiquilin-1 expression was found to decline in human brain according
to  the  severity  of  AD.  The in vitro and in vivo data suggest that overexpression of
ubiquilin-1 increases BACE1 protein levels. The results of in vitro studies indicate
that ubiquilin-1 overexpression leads to the stabilization of BACE1 due to decreased
degradation in the lysosomal compartment. These findings suggest that the
interrelationship of BACE1 and ubiquilin-1 and their altered levels and function may
play a role in AD pathogenesis.
In summary, the studies included in this thesis provide novel information on the genetic
and the functional role of important factors, such as LXR, GGA3, eIF2 and ubiquilin-1, in
AD pathogenesis. These findings increase the knowledge of crucial events in AD
pathogenesis at the molecular level and may thus represent new potential targets for
biomarker and drug research. AD research is now entering the post-genomic era. It appears
that the GWAS studies with very large sample cohorts have made candidate gene-based
studies redundant, and it is unlikely that new common variants with high risk effects will
be found. Thus, in the future, the research will focus on revealing the biological functions of
the already known risk genes. On the other hand, the genetic research will likely focus
more on understanding the epigenetic regulation of the risk genes. However, the research
settings employed in this thesis will be important also in the future in the applications of
personalized medicine, when the responses of individuals with different genetic
backgrounds to various pharmacological treatments, such as LXR/RXR or APOE targeted
drugs, need to be evaluated.
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Alzheimer’s disease (AD) is a neuro-
degenerative disease with a complex 
genetic background. Several risk 
genes have been identified in AD, 
but for the most part, their biological 
function in the disease pathogenesis 
is still elusive. This thesis focuses on 
elucidating the genetic and biologi-
cal mechanisms of known as well as 
novel risk genes in the molecular 
pathogenesis of AD. The primary 
focus is set to NR1H3, GGA3 and 
UBQLN-1 genes. These studies ad-
vance our knowledge related to mo-
lecular mechanisms of AD and may 
provide new potential targets for the 
development of novel biomarkers and 
therapeutic interventions in AD.
